



# Systematic Review Sarcopenia Adversely Affects Outcomes following Cardiac Surgery: A Systematic Review and Meta-Analysis

Ali Ansaripour <sup>1,†</sup>, Arian Arjomandi Rad <sup>2,†</sup>, Marinos Koulouroudias <sup>3</sup>, Dimitrios Angouras <sup>4</sup>, Thanos Athanasiou <sup>5</sup> and Antonios Kourliouros <sup>1,\*</sup>

- <sup>1</sup> Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK; ali.ansaripour@gtc.ox.ac.uk
- <sup>2</sup> Medical Sciences Division, University of Oxford, Oxford OX1 3AZ, UK
- <sup>3</sup> Department of Cardiac Surgery, Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK
- <sup>4</sup> Department of Cardiac Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, 10679 Athens, Greece
- <sup>5</sup> Department of Surgery and Cancer, Imperial College London, London SW7 2BX, UK
- \* Correspondence: antonios.kourliouros@ouh.nhs.uk; Tel.: +44-(0)-1865-226167
- <sup>+</sup> These authors contributed equally to this work.

**Abstract:** Background: Sarcopenia is a degenerative condition characterised by the loss of skeletal muscle mass and strength. Its impact on cardiac surgery outcomes remains poorly investigated. This meta-analysis aims to provide a comprehensive synthesis of the available evidence to determine the effect of sarcopenia on cardiac surgery outcomes. Methods: A systematic review and meta-analysis followed PRISMA guidelines from inception to April 2023 in EMBASE, MEDLINE, Cochrane database, and Google Scholar. Twelve studies involving 2717 patients undergoing cardiac surgery were included. Primary outcomes were early and late mortality; secondary outcomes included surgical time, infection rates, and functional outcomes. Statistical analyses were performed using appropriate methods. Results: Sarcopenic patients (906 patients) had a significantly higher risk of early mortality (OR: 2.40, 95% CI: 1.44 to 3.99, p = 0.0007) and late mortality (OR: 2.65, 95% CI: 1.57 to 4.48, p = 0.0003) compared to non-sarcopenic patients (1811 patients). There were no significant differences in overall surgical time or infection rates. However, sarcopenic patients had longer ICU stays, higher rates of renal dialysis, care home discharge, and longer intubation times. Conclusion: Sarcopenia significantly increases the risk of early and late mortality following cardiac surgery, and sarcopenic patients also experience poorer functional outcomes.

Keywords: sarcopenia; cardiac surgery; frailty

# 1. Introduction

Sarcopenia, a degenerative condition characterised by the progressive and generalised loss of skeletal muscle mass and strength, is increasingly recognised as a significant health concern [1]. It is commonly associated with aging, and its prevalence is particularly noticeable in the elderly. Sarcopenia has been linked to a broad range of adverse health outcomes, including impaired physical function, increased risk of falls, prolonged recovery periods, and higher mortality rates [2]. In the context of cardiac surgery, sarcopenia's implications are even more profound. As surgical techniques and medical management continue to advance, a growing number of older adults are becoming candidates for cardiac surgery. However, age-related conditions like sarcopenia pose unique challenges in this demographic, often complicating their post-operative recovery and overall prognosis [3,4].

Despite the mounting evidence demonstrating the impact of sarcopenia on surgical outcomes, it remains a poorly recognised and underdiagnosed entity in cardiac surgery. This discrepancy, in part, could be attributed to the complexity surrounding the diagnostic criteria of sarcopenia. There is no universal consensus on the definition of sarcopenia,



Citation: Ansaripour, A.; Arjomandi Rad, A.; Koulouroudias, M.; Angouras, D.; Athanasiou, T.; Kourliouros, A. Sarcopenia Adversely Affects Outcomes following Cardiac Surgery: A Systematic Review and Meta-Analysis. *J. Clin. Med.* **2023**, *12*, 5573. https://doi.org/10.3390/ jcm12175573

Academic Editor: Marco Alessandro Minetto

Received: 27 July 2023 Revised: 15 August 2023 Accepted: 21 August 2023 Published: 26 August 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). with multiple working groups suggesting different guidelines. Notably, the European Working Group on Sarcopenia in Older People (EWGSOP) [5], the Asian Working Group for Sarcopenia (AWGS) [6], and the Foundation for the National Institutes of Health [7] each provide their unique sets of criteria, differing in their approach to quantifying muscle mass, muscle strength, and physical performance. This variability in diagnostic criteria has led to discrepancies in reported prevalence rates and has created challenges in comparing results across studies. In the past decade, the body of research investigating the impact of sarcopenia on cardiac surgery has grown substantially. Still, the findings have been somewhat inconsistent due to variations in study designs, the heterogeneity in patient populations, and the divergence in defining sarcopenia.

While obesity has been studied extensively and identified as a risk factor for poor outcomes in cardiac surgery [8,9], body mass index (BMI) is an inaccurate indicator of the relationship between adiposity and muscle mass [10]. Indeed, a sarcopenic patient can exhibit a normal or even elevated BMI that would qualify them as having sarcopenic obesity, a condition disregarded in previous studies only concentrating on BMI on cardiac surgical outcomes [11].

Through this meta-analysis, we aim to provide a more robust estimate of the actual effect size of sarcopenia on cardiac surgery outcomes. By highlighting the burden of sarcopenia in cardiac surgery, we hope to promote the development of targeted interventions and the incorporation of sarcopenia screening into preoperative evaluations. Furthermore, this analysis could provide insights into future research areas, particularly interventional studies aiming to mitigate the impact of sarcopenia on cardiac surgery outcomes.

# 2. Materials and Methods

# 2.1. Literature Search Strategy

A systematic review and meta-analysis was conducted in accordance with the Cochrane Collaboration published guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A literature search was conducted of EMBASE, MEDLINE, Cochrane, PubMed, and Google Scholar from inception to April 2023 (Figure 1). The search terms used were: ("Sarcopenia" OR "Muscle Wasting" OR "Muscle Mass" or "Muscle Atrophy") AND ("Cardiac Surgery" OR "Cardio-thoracic Surgery" OR "Heart Surgery" or "Surgical Aortic Valve Replacement" or "Coronary Artery Bypass Grafting" or "aortic surgery" or "mitral valve surgery"). Further articles were identified using the 'related articles' function on MEDLINE and a manual search of the references lists of articles found through the original search. The only limits used were the English language and the mentioned time frame. Patient consent and institutional review board approval were unnecessary in this study as no patients were recruited.

#### 2.2. Study Inclusion and Exclusion Criteria

All original comparative articles of patients with or without sarcopenia undergoing adult cardiac surgery and reporting on mortality and morbidity outcomes were included. Studies were excluded from the review if: (1) inconsistencies in the data precluded valid extraction; (2) the study was performed in an animal model; (3) studies did not have a comparison group; or (4) the size of the study population was small (<10 patients). Case reports, reviews, abstracts from meetings and preclinical studies were excluded. Using the above criteria, two reviewers (AA and A.AR.) independently selected articles for further assessment after the title and abstract review. A third independent reviewer (T.A.) resolved disagreements between the two reviewers. Potentially eligible studies were then retrieved for full-text assessment.



Figure 1. PRISMA Flow Chart.

# 2.3. Data Extraction and Critical Appraisal

All full texts of retrieved articles were read and reviewed by two authors (A.A. and A.AR.), and the inclusion or exclusion of studies was decided unanimously. When there was disagreement, a third reviewer (T.A.) made the final decision. Using a pre-established protocol, the following data were extracted: first author, study type and characteristics, number of patients, population demographics, stroke rate, overall stroke rate, major bleeding, cardiopulmonary bypass (CBP) time, hospital length of stay, kidney dysfunction, early mortality, and overall mortality. For this review, a data extraction sheet was developed and pilot-tested on three randomly selected included studies, whereupon the sheet was refined accordingly. Data extraction was performed by two review authors (A.A and A.AR.). A third author (T.A.) validated the correctness of the tabulated data. Potential inter-reviewer disagreements were resolved by consensus. Primary outcomes were early/overall mortality. Secondary outcomes were hospital length of stay (LOS), intensive care unit (ICU) LOS, cross-clamp (CC) time, CBP time, overall surgery time, postoperative arrhythmias, sternal wound infection, stroke, kidney failure, discharge to care home, and intubation time.

#### 2.4. Data Analysis

Odds ratios (OR) with 95% confidence interval (CI) and *p*-values were calculated for each categorical clinical outcome. Additionally, we utilised the Mean Difference (MD) as a statistical analysis method to analyze continuous data in our meta-analysis. MD enabled us to quantify the absolute difference in means between two groups, providing insights into the magnitude of effect size. Forest plots were created to represent the clinical outcomes. Chi-squared and I2 tests were executed for the assessment of statistical heterogeneity. Using a Mantel-Haenszel random-effects model, the ORs were combined across the studies. Funnel plots were constructed to assess publication bias. All analyses

were completed through the "metafor" package in R Statistical Software (version 4.0.2) (Foundation for Statistical Computing, Vienna, Austria). A two-tailed *p*-value < 0.05 was considered statistically significant.

# 2.5. Sensitivity Analysis

The influence of a single study on the overall effect of sarcopenic versus non-sarcopenic patients undergoing adult cardiac surgery on the primary outcome was assessed by sequentially removing one study (the "leave-one-out" method). This sensitivity analysis was carried out to test the consistency of results to investigate if individual studies had an excessive impact on the analysis across all outcomes.

#### 3. Results

#### 3.1. Description of Studies

The literature search identified 336 articles. Of these, 57 relevant articles were read in full and assessed according to our inclusion and exclusion criteria. Following critical appraisal, a total of 12 studies [12–23] incorporating a total of 2717 patients were included. The studies described outcomes of sarcopenic (906) versus non-sarcopenic (1811) patients undergoing adult cardiac surgery. Figure 1 illustrates the study selection process.

#### 3.2. Baseline Characteristics

There were 2717 patients included in this meta-analysis, of which there are 906 sarcopenic and 1811 non-sarcopenic patients. The data on baseline characteristics can be found in Table 1, Supplementary Figure S1. The mean age of the patients in the sarcopenic and non-sarcopenic cohorts was 70.57 and 65.36 years, respectively. In terms of BMI, the mean for the sarcopenic group was 22.21, while for the non-sarcopenic group, it was 23.73. The mean Left Ventricular Ejection Fraction (LVEF) percentages were 57.32% and 57.86% for the sarcopenic and non-sarcopenic groups, respectively. Lastly, the mean psoas muscle area index for the sarcopenic group was 478.2  $\text{mm}^2/\text{m}^2$ ; for the non-sarcopenic group, it was 819.6  $\text{mm}^2/\text{m}^2$ . The mean percentages of sarcopenic and non-sarcopenic patients with diabetes were 41.60% and 34.41%, respectively. Similarly, the mean percentages of sarcopenic and non-sarcopenic patients with hypertension were 70.39% and 73.20%, respectively. In the case of chronic kidney disease, the mean percentages were 24.38% for the sarcopenic and 17.65% for the non-sarcopenic group.

# 3.3. Primary and Secondary Outcomes

3.3.1. Early Mortality and Late Mortality

Sarcopenic patients were compared with non-sarcopenic patients, with ten studies reporting on early mortality outcomes postoperatively (Figure 2A). The overall OR for early mortality showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: OR: 2.40; 95% CI: 1.44 to 3.99; p = 0.0007). There was evidence of no heterogeneity among studies reporting on early mortality.

Sarcopenic patients were compared with non-sarcopenic patients, with seven studies reporting on late mortality outcomes postoperatively (Figure 2B). The overall OR for late mortality showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: OR: 2.65; 95% CI: 1.57 to 4.48; p = 0.0003). There was evidence of high heterogeneity among studies reporting on late mortality.

**Table 1.** Baseline characteristics of the included studies for both sarcopenic (SP) and non-sarcopenic (NSP) cohorts. Study designs included prospective (P) or retrospective (R) studies. Studies defined sarcopenia according to psoas muscle index (PMI), skeletal muscle index (SMI) on CT scan, Asian Working Group for Sarcopenia (AWGS), or European Working Group on Sarcopenia in Older People (EWGSOP). Not applicable (NA) has been used where studies do not report the specific parameter's data. Left Ventricular Ejection Fraction (LVEF), Body Mass Index (BMI).

Study	Patient Study Numbers		Study	Country	AGE				BMI					LVI	EF %		Psoas Muscle Area Index (mm <sup>2</sup> /m <sup>2</sup> )			
(SP.NSP)	Definition	Design	Country	Mean SP	SD SP	Mean NSP	SD NSP	Mean SP	SD SP	Mean NSP	SD NSP	Mean SP	SD SP	Mean NSP	SD NSP	Mean SP	SD SP	Mean NSP	SD NSP	
Shibasaki et al., 2022	72/120	SMI: total body muscle	R	Japan	73.8	8.8	67.0	10.1	21.5	3.0	24.5	4.3	56.2	13.3	59.4	12.3	NA	NA	NA	NA
Kondo et al., 2022	29/111	PMI	R	Japan	81.0	5.8	77.3	4.7	21.6	4.2	22.8	3.7	62.2	9.0	62.1	9.0	704.0	112.0	1083.0	290.0
Okamura et al., 2020	76/228	PMI	Р	Japan	69.9	8.9	66.6	9.7	21.6	3.0	24.1	3.3	55.5	14.4	56.4	13.9	168.0	37.0	283.0	65.0
Yuenyongchaiwat et al., 2020	43/117	AWGS	R	Thailand	66.4	10.7	59.1	11.2	NA	NA	NA	NA	53.3	15.1	51.9	13.7	NA	NA	NA	NA
Oh et al., 2020	73/71	SMI: pec. major & erector spinae	R	South Korea	59.5	13.1	60.4	10.6	22.6	3.2	24.4	3.0	60.0	3.0	60.0	3.0	NA	NA	NA	NA
Kurumisawa et al., 2019	35/103	PMI	R	Japan	67	10	66	9	19.5	2.9	22.6	3.8	50	15	52	16	NA	NA	NA	NA
Hawkins et al., 2018	60/180	PMI	R	USA	81	2	80	2.5	NA	NA	NA	NA	57	3	57	2.5	670.0	220.0	1060.0	280.0
Yamashita et al., 2017	387/386	PMI	R	Japan	65.5	13.2	64.4	13.1	23.4	3.53	21.1	3.45	57.8	12.5	56.7	13.1	401	78	667	111
Ikeno et al., 2017	81/185	PMI	R	Japan	76.2	5.6	45.7	5.7	22.5	3.4	23.8	2.9	NA	NA	NA	NA	NA	NA	NA	NA
Teng et al., 2019	67/175	EWGSOP	R	Japan	66.4	12.4	58.9	11.2	21.7	2.7	26.2	3.5	64.1	11.8	62.3	13.1	NA	NA	NA	NA
Shen et al., 2023	44/294	SMI: T12 level muscle	Р	China	65.0	8.2	65.0	7.4	25.0	2.9	24.4	3.1	NA	NA	NA	NA	NA	NA	NA	NA
Kiriya et al., 2020	63/143	PMI	R	Japan	75.1	5.5	73.9	5.5	22.7	3.4	23.4	3.7	57.1	13.6	60.8	34.9	448.0	143.5	1005.0	312.5

References: [12-23].

# A. Early Mortality

Sarcopen		enia	No Sarco	penia		Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl			
Shen et al. 2023	5	44	12	294	21.6%	3.01 [1.01, 9.01]	2023				
Kondo et al. 2022	2	29	0	111	2.8%	20.27 [0.95, 434.49]	2022	· · · · · · · · · · · · · · · · · · ·			
Shibasaki et al. 2022	1	72	0	120	2.5%	5.06 [0.20, 125.78]	2022				
Oh et. 2020	5	73	1	71	5.5%	5.15 [0.59, 45.21]	2020				
Okamura et al. 2020	3	76	1	228	5.0%	9.33 [0.96, 91.07]	2020	· · · · · · · · · · · · · · · · · · ·			
Kiryia et al. 2020	3	63	2	143	7.9%	3.52 [0.57, 21.64]	2020				
Kurumisawa et al. 2019	6	35	7	103	19.0%	2.84 [0.88, 9.11]	2019				
Teng et al. 2019	1	67	5	175	5.5%	0.52 [0.06, 4.49]	2019				
Hawkins et al. 2018	3	60	10	180	14.8%	0.89 [0.24, 3.36]	2018				
lkeno et al. 2017	4	81	6	185	15.5%	1.55 [0.43, 5.65]	2017				
Total (95% CI)		600		1610	100.0%	2.40 [1.44, 3.99]		•			
Total events	33		44								
Heterogeneity: Tau <sup>2</sup> = 0.00	; Chi <sup>2</sup> = 8.	.84, df =	9 (P = 0.4	5);  ² = 0	%		L				
Test for overall effect: Z = 3	.37 (P = 0	0.0007)					0.01	Favours Sarcopenia Favours No Sarcopenia			

# B. Late Mortality

	Sarcopenia No Sarcopenia					Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI			
Shen et al. 2023	12	44	18	294	14.1%	5.75 [2.54, 13.02]	2023				
Okamura et al. 2020	23	76	17	228	15.6%	5.39 [2.69, 10.80]	2020				
Kurumisawa et al. 2019	20	35	49	103	14.7%	1.47 [0.68, 3.18]	2019				
Teng et al. 2019	2	57	7	146	7.2%	0.72 [0.15, 3.58]	2019				
Hawkins et al. 2018	15	60	23	180	15.2%	2.28 [1.10, 4.72]	2018				
Ikeno et al. 2017	30	81	21	185	16.3%	4.59 [2.42, 8.71]	2017				
Yamashita et al. 2017	29	386	21	387	17.0%	1.42 [0.79, 2.53]	2017	+			
Total (95% CI)		739		1523	100.0%	2.65 [1.57, 4.48]		+			
Total events	131		156					8550			
Heterogeneity: Tau <sup>2</sup> = 0.33	; Chi <sup>2</sup> = 1	9.82, df	= 6 (P = 0.0	003); I <sup>2</sup> =	: 70%		F				
Test for overall effect: Z = 3	8.64 (P = 0	0.0003)					U	Favours Sarcopenia Favours No Sarcopenia			

**Figure 2.** Forest Plots for the primary outcomes. (**A**) Early Mortality; (**B**) Late Mortality. References [12–14,17–23].

# 3.3.2. Overall Surgery Time

Sarcopenic patients were compared with non-sarcopenic patients, with five studies reporting overall surgery time (Figure 3A). The overall MD for overall surgery time showed no statistically significant difference between the two groups (random-effects model: MD: -0.21; 95% CI: -8.85 to 8.43; p = 0.96). There was evidence of no heterogeneity among studies reporting on overall surgical time.

# 3.3.3. CBP Time

Sarcopenic patients were compared with non-sarcopenic patients, with nine studies reporting on CBP time (Figure 3B). The overall MD for CBP time showed no statistically significant difference between the two groups (random-effects model: MD: 2.25; 95% CI: -1.55 to 6.04; p = 0.25). There was evidence of no heterogeneity among studies reporting on CBP time.

#### 3.3.4. CC Time

Sarcopenic patients were compared with non-sarcopenic patients, with five studies reporting on CC time (Figure 3C). The overall MD for CC time showed no statistically significant difference (random-effects model: MD: 0.52; 95% CI: -3.31 to 4.36; p = 0.79). There was evidence of no heterogeneity among studies reporting on CC time.

#### 3.3.5. Hospital LOS

Sarcopenic patients were compared with no-sarcopenic patients, with nine studies reporting on Hospital LOS (Figure 3D). The overall MD for Hospital LOS showed no statistically significant difference (random-effects model: MD: 1.47; 95% CI: 0.00 to 2.93; p = 0.05). There was evidence of high heterogeneity among studies reporting on Hospital LOS.

# A. Overall surgical time

Mean Min	1 SD [Min]	Total	Mean [Min]	SD [Min]	Total	Weight	V. Random, 95% CI (Mi	n] Year		IV. Random.	95% CI IMin	1	
38	8 102	35	378	109	103	4.7%	10.001-29.81 49.8	11 2019			+	_	
2020 224	9 129 2	13	240 4	179.9	117	3 296	-74 50 [-71 07 22 0	71 2013					
2020 324.	3 130.3	40	250.4	120.0	120	5.370	12 20 1 22 06 60 2	1 2020					
3/1.	3 119	12	100.0	138.9	120	0.470	13.20 - 23.80, 30.2	0 2022					
19	3 30.4	29	195.5	40.8	111	41.5%	-2.50 [-15.92, 10.9	2] 2022					
21	5 40.7	44	214	40	294	45.1%	1.00 [-11.87, 13.8	7] 2023					
		223			745	100.0%	-0.21 [-8.85, 8.4	3]		•			
00; Chi <sup>2</sup> = 1.91, df:	= 4 (P = 0.75	5); P= 09	6						-			1	400
= 0.05 (P = 0.96)									-100	-50 Favours Sarcopenia	Favours N	o Sarcopen	ia
me													
Mean IM	arcopenia	1 Total	No Sa Mean [Min]	SD [Min]	Tota	Weight	Mean Difference	Min1 V	ar	Mean (	Difference	tin1	
184	4 67	5 81	173.2	48.2	18	5 55%	11 20 65 06 2	7 461 20	17	IV, Railuoli		1001	
1	05 33.	5 60	103.5	37	180	0 14.3%	1.50 [-8.55, 1	1.551 20	18		-		
177	.5 79.	6 63	172.6	68.4	143	3 2.8%	4.90 [-17.73, 2	7.53] 20	19	-			
119	.5 37.	1 67	123.9	43.6	175	5 12.0%	-4.40 [-15.38,	6.58) 20	19		+		
1	19 19.	8 73	116	20	71	34.1%	3.00 [-3.50,	9.50] 20	20		+		
2020 112.	28 56.	9 43	104.53	49.4	113	3 3.9%	7.75 -11.54, 2	7.04) 20	20	-			
92	4 21.	0 29	90.2	14.8	111	20.8%	2.20 [-6.13, 1	2 601 ~	122				
1	52 64	5 12	180.4	76.2	12	3.0%	1.60 - 20.48, 2	3.08 20	122				
2	01.	9 44	62.5	01.5	29	- 3.8%	-0.50 [-19.98, 1	0.90j 2l	23				
.00; Chi <sup>2</sup> = 3.09, dt	= 8 (P = 0.9	532 33); I² = (	1%		1392	2 100.0%	2.25 [-1.55,	6.04]	-10	0 -50	1	50	100
10(0.23)										Favours (experimental	[] Favours	[control]	
Sarcop	enia		No Sarcop	enia			Mean Difference			Mean Di	fference		
Mean [Min] SI	[Min] To	tal Me	an (Min) SD	[Min] To	tal W	leight IV	, Random, 95% CI [Min	] Year		IV, Random,	95% CI [Mi	n]	
79.5	29.7	81	75.5	28.4 1	85 2	25.1%	4.00 [-3.65, 11.6	5] 2017			-		
69	23.5	60	73	30 1	80 2	7.0%	-4.00 [-11.39, 3.3	2018		-	t		
127	67	60									-		
	- 57	03	123.5	42.3 1	43	6.0%	3.50 [-12.19, 19.1	2020					
60.9	16.1	03 29	123.5 60.8	42.3 1	43 11 3	6.0% 8.2%	3.50 [-12.19, 19.1 0.10 [-6.11, 6.3	0] 2020		-	-		
60.9 129.5	16.1 68.2	03 29 72	123.5 60.8 120.1	42.3 1 11 1 67.7 1	43 11 3 20	6.0% 8.2% 3.7%	3.50 [-12.19, 19.1 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2	9] 2020 1] 2022 7] 2022		-	-		
60.9 129.5	16.1 68.2	29 72	123.5 60.8 120.1	42.3 1 11 1 67.7 1	43 11 3 20	6.0% 8.2% 3.7%	3.50 [-12.19, 19.1 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2	0] 2020 1] 2022 7] 2022			-		
60.9 129.5	57 16.1 68.2 3	03 29 72 05	123.5 60.8 120.1	42.3 1 11 1 67.7 1 7	43 11 3 20 39 10	6.0% 88.2% 3.7% 00.0%	3.50 [-12.19, 19.1 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3	8] 2020 1] 2022 7] 2022		-			
60.9 129.5 0.00; Chi#= 3.16, 2= 0.27 (P = 0.79)	57 16.1 68.2 3 ff = 4 (P = (	83 29 72 05 0.53); I²∶	123.5 60.8 120.1 = 0%	42.3 1 11 1 67.7 1 7	43 11 3 20 39 10	6.0% 38.2% 3.7%	3.50  -12.19, 19.1 0.10  -6.11, 6.3 9.40  -10.47, 29.2 0.52 [-3.31, 4.3	8] 2020 1] 2022 7] 2022	-100	-50 Favours Sarcopenia	0 Favours S	50 sarcopenia	100
60.9 129.5 0.00; Chi#= 3.16, 2= 0.27 (P = 0.79) tal LOS	57 16.1 68.2 3 ff = 4 (P = (	83 29 72 05 0.53); I <sup>a</sup> ∶	123.5 60.8 120.1 = 0%	42.3 1 11 1 67.7 1 7	43 11 3 20 39 10	6.0% 88.2% 3.7%	3.50 (-12.19, 19.1) 0.10 (-6.11, 6.3 9.40 (-10.47, 29.2) 0.52 (-3.31, 4.3)	8] 2020 1] 2022 7] 2022	-100	-50 Favours Sarcopenia	Favours S	50 Sarcopenia	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, := 0.27 (P = 0.79) tal LOS	16.1 68.2 3 df = 4 (P = 0	83 29 72 05 ).53); I²∶	123.5 60.8 120.1 = 0%	42.3 1 11 1 67.7 1 7	43 11 3 20 39 10	6.0% 8.2% 3.7%	3.50 (-12.19, 19.1) 0.10 (-6.11, 6.3 9.40 (-10.47, 29.2) 0.52 (-3.31, 4.3)	8] 2020 1] 2022 7] 2022	-100	-50 Favours Sarcopenia Mean D	0 Favours S	50 Sarcopenia	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, := 0.27 (P = 0.79) tal LOS Sa Mean [Days	57 16.1 68.2 3 df = 4 (P = ( rcopenia } SD (Days	03 29 72 05 0.53); I² :	123.5 60.8 120.1 = 0% No Sa Mean (Days)	42.3 1 11 1 67.7 1 7 arcopenia SD [Days	43 11 3 20 39 10	6.0% 18.2% 3.7% 00.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0	8] 2020 1] 2022 7] 2022 6]	-100 ar	-50 Favours Sarcopenia Mean D IV, Random,	Favours S	50 sarcopenia	100
0.00; Chi <sup>#</sup> = 3.16; 129.5 0.00; Chi <sup>#</sup> = 3.16; t = 0.27 (P = 0.79) tal LOS <u>Mean [Days</u> 2	16.1 16.2 3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53);   <sup>2</sup> : ] <u>Total</u> 8 81	123.5 60.8 120.1 = 0% <u>No Sa</u> <u>Mean [Days]</u> 22	42.3 1 11 1 67.7 1 7 arcopenia <u>SD [Days</u> 14.3	43 11 3 20 39 10 39 10	6.0% 18.2% 3.7% 00.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-0.03]	ays] 2020 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2022 2020 2022 2020 2020 2020 2020 2020 2022 2020 2022 202 202 202 202 202 202 202 202 202 202 202 202 202 20	-100 ar	-50 Favours Sarcopenia Mean D IV, Random,	Favours S	50 Sarcopenia	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, ( = 0.27 (P = 0.79) tal LOS Mean [Days 2 2 2	16.1 16.2 3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53);   <sup>2</sup> : ] <u>Total</u> 8 81 3 60	123.5 60.8 120.1 = 0% No Sa <u>Mean [Days]</u> 22 7	42.3 1 11 1 67.7 1 7 so [Days 14.5	43 11 3 20 39 10 <u>39 10</u> 5 18: 4 18:	6.0% 82.2% 3.7% 00.0% al Weight 5 8.6% 0 22.1%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-0.03, 0.50 [-0.46,	ays] Ye 3.031 20 1] 2022 2] 2022 3] 3] 4 4 8.031 20 1.461 20	-100 ar 17 18	-50 Favours Sarcopenia Mean D IV, Random,	Favours S 95% CI (Day	50 sarcopenia rs]	100
0.00; Chi <sup>#</sup> = 3.16, = 0.27 (P = 0.79) tal LOS Mean [Days 2 7;	16.1 16.2 3 3 4f = 4 (P = ( rcopenia ) <u>SD [Days</u> 6 15. 5 9 2.	03 29 72 05 0.53);  ² : 1 <u>3</u> 60 2 35	123.5 60.8 120.1 = 0% <u>No Sa</u> <u>Mean (Days)</u> 22 7 7 37	42.3 1 11 1 67.7 1 7 srcopenia <u>SD [Days</u> 14.3 5	43 11 3 20 39 10 39 10 5 18 4 18 1 10	6.0% 8.2% 3.7% 00.0% Meight 5 8.6% 0 22.1% 3 1.4%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-0.03, 0.50 [-0.46, -8.00 [-20.25,	aysj Ye 3.033 20 4.461 20 4.251 20	+	-50 Favours Sarcopenia Mean D IV, Random,	Favours S Difference 95% CI (Day	50 sarcopenia rs)	100
60.9 129.5 0.00; Chi≇= 3.16, = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 2 19	16.1 16.2 3 3 3 3 5 5 5 5 4 15 5 15 5 15 15 15 15 15 15	03 29 72 05 0.53);  ² : 1 <u>7</u> 1 5 3 8 8 8 1 3 60 2 35 3 67	123.5 60.8 120.1 = 0% <u>Mean (Days)</u> 22 7 37 15.3	42.3 1 11 1 67.7 1 7 so (Days 50 (Days 14.3 8.4	43 11 3 20 39 10 39 10 5 18 4 18 1 10 4 17	6.0% 8.2% 3.7% 00.0% M Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.30 Mean Difference IV, Random, 95% CI [D 4.00 [-0.03, 0.55 [-0.46, -8.00 [-20.25, 4.10 [0.75,	aysj Ye 3.033 20 4.461 20 5.451 20 5.451 20 5.451 20 5.451 20	+	-50 Favours Sarcopenia Mean D IV, Random,	Favours S	50 Sarcopenia (*)	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16; := 0.27 (P = 0.79) tal LOS Mean (Days 2 19; 32;	16.1 16.2 3 3 3 3 3 5 5 5 2 4 1 4 3 0 1 5 1	03 29 72 05 0.53); I <sup>a</sup> = 1 3 8 8 8 8 8 3 6 3 6 3 6 3 6 3 6 3	123.5 60.8 120.1 = 0% <u>No Sa</u> <u>Mean (Days)</u> 7 7 37 15.3 27	42.3 1 11 1 67.7 1 7 so [Days 14.3 5 8. 21.1	43 11 3 20 39 10 39 10 5 18 5 18 4 18 1 10 4 17 9 14	6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-00.2, 4.00 [-00.2, 4.10 [0.75, 5.40 [-2.87, 1]	ays] Ye 3.03] 20 3.03] 20 1.46] 20 4.25] 20 3.77] 20	-100 -100 17 18 19 19 20	-50 Favours Sarcopenia Mean D IV, Random,	Favours S 95% CI [Day	50 sarcopenia rs]	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, 1 = 0.27 (P = 0.79) tal LOS Mean (Days 7, 2 7, 19, 32,	57 16.1 68.2 3 1f = 4 (P = ( rcopenia ) <u>SD (Days</u> 6 15. 5 2 4 1: 4 30 4 5. 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53);  *: 0 0 5 0 5 1 6 6 5 73	123.5 60.8 120.1 = 0% <u>Mean (Days)</u> 22 7 37 15.3 27 5.3 27 6	42.3 1 11 1 67.7 1 7 so (Days 50 (Days 14.3 5 8. 21.1 8. 21.1 8.	43 11 3 20 39 10 39 10 5 18: 4 18: 1 10: 4 17: 9 14: 5 7	6.0% 18.2% 3.7% 00.0% 1 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 1 15.1%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3] 9.40 [+10.47, 29.2] 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [] 4.00 [+0.03, 0.50 [+0.46, -8.00 [+2.25, 4.10 [0.75, 5.40 [+2.87, 1] -2.00 [+3.5],	ays] Ye 3.03] 2022 3] 4] 4] 4] 4] 4] 4] 4] 4] 4] 4] 4] 4] 4]	-100 -100 ar 17 18 19 20 20	-50 Favours Sarcopenia Mean D IV, Random,	Favours S 95% CI (Day	50 arcopenia	100
60.9 129.5 0.00; Chi≇ = 3.16, = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 2 7, 2 1 32. 020 9.	16.1 68.2 3 df = 4 (P = ( <u>) SD [Days</u> 6 15.5 5 9 2 4 1.1 4 30.1 4 5.3 3 3.1	03 29 72 05 0.53);   <sup>2</sup> : 0 3 0 5 3 6 6 6 3 5 73 8 43 5 73 8 43	123.5 60.8 120.1 0% No Sa <u>Mean (Days)</u> 22 7 37 15.3 27 6 6 7.2	42.3 1 11 1 67.7 1 7 srcopenia <u>SD (Days</u> 14.3 5 8.4 21.1 8.4 21.1 8.4	43 11 3 20 39 10 39 10 5 18: 4 18: 1 10: 4 17: 9 14: 5 7: 2 11: 5 7: 2 11: 5 7: 2 11: 5 7: 2 11: 5 7: 2 11: 5 7: 2 11: 5 7: 5 7: 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 7 21.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI[ 4.00 [-0.03, 0.50 [-0.46, -8.00 [-20.25, 4.10 [0.75, 5.40 [-2.97,1] -2.00 [4.35, 2.10 [0.91,	ays] Ye 3.03] 20 4.25] 20 3.03] 20 4.45] 20 4.25] 20 7.45] 20 3.27] 20 3.35] 20 3.29] 20	ar -100 17 18 19 20 20 20	-50 Favours Sarcopenia IV, Random,	Favours S Difference 95% CI (Day	50 sarcopenia (rs)	100
60.9 129.5 0.00; Chi <sup>µ</sup> = 3.16, i = 0.27 (P = 0.79) tal LOS Mean [Days 2 7; 2 7; 19, 32 020 9, 31/	57 16.1 68.2 3 3 3 3 5 5 5 5 2 4 15.1 5 5 2 4 5 3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53);  ₽ = 0.53);  P = 0.53);  P = 0.53);  P = 0.53];  P = 0.53];  P = 0.53];  P = 0.55];  P = 0.55]	123.5 60.8 120.1 = 0% Mean (Days) 22 7 37 15.3 27 6 7.2 22,7 22,7	42.3 1 11 1 67.7 1 7 so (Days 8.1 21.1 8.1 21.1 8.1 21.1 8.1 21.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1 8.1	43 11 3 20 39 10 5 18 4 18 1 10 4 18 1 10 9 14 5 7 2 11 5 12 1	6.0% 18.2% 3.7% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 1 15.1% 7 21.0% 0 2.6%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [+10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [[ 4.00 [+0.3, 0.50 [+0.46, -8.00 [+2.97, 1 -2.00 [+3.5, 2.10 [0.91, 8.90 [0.29, 1]	ays] Ye 3.03] 2022 7] 2022 7] 2022 8] 8.03] 20 4.25] 20 7.45] 20 8.77] 20 8.77] 20 8.77] 20 8.77] 20 8.75] 20 8.75] 20	ar -100 17 18 19 20 20 20 22	-50 Favours Sarcopenia IV, Random,	Favours S httlerence 95% CI (Day	50 sarcopenia	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, 1 = 0.27 (P = 0.79) tal LOS Mean [Days 7, 7, 7, 19, 32, 020 9, 31, 11	16.1 16.2 3 df = 4 (P = ( 1 SD (Days 3 SD (Days 3 SD (Days 4 1: 4 30. 4 30. 4 30. 5 33. 1 7.	03 29 72 05 0,53); I <sup>2</sup> : 1 3 6 8 8 1 3 6 0 2 3 5 6 3 6 7 2 3 5 8 4 3 7 7 2 4 4 4	123.5 60.8 120.1 = 0% Mean [Days] 22 7 37 15.3 27 6 7.2 22.7 10	42.3 1 11 1 67.7 1 7 80 [Days 50 [Days 8. 21.1 8.8 21.1 8.2 20.0 20.0 20.0 20.0 20.0 20.0 20.0	43 11 3 20 39 10 39 10 5 18 4 18 1 10 4 18 1 10 4 18 1 10 4 18 1 10 4 18 1 10 4 18 1 10 1 4 5 7 7 2 1 11 5 12 3 29	6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 1 15.1% 7 21.0% 0 2.6% 4 15.7%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [+10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [+0.03, 0.50 [+0.46, -8.00 [+20.25, 4.10 [0.75, 5.40 [+2.97, 1] -2.00 [+3.3, 2.10 [0.91, 8.90 [0.29, 1] 1.00 [+1.21,	<ul> <li>ays] 2020</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>3]</li> <li>ays] Ye</li> <li>axes</li> <li>axes</li> <li>Ye</li> <li>axes</li> <li>axes</li> <li>xe</li> <li>xe<td>4 -100 -100 -100 -100 -100 -100 -100 -10</td><td>-50 Favours Sarcopenia Mean D IV, Random,</td><td>Favours S bifference 95% CI (Day</td><td>50 tarcopenia rs]</td><td>100</td></li></ul>	4 -100 -100 -100 -100 -100 -100 -100 -10	-50 Favours Sarcopenia Mean D IV, Random,	Favours S bifference 95% CI (Day	50 tarcopenia rs]	100
60.9 129.5 0.00; Chi≇ = 3.16, = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 2 2 7, 2 9, 32, 020 9, 31, 1	16.1 68.2 3 df = 4 (P = ( ) SD [Days 6 15.1 5 9 2: 4 1: 4 30.0 4 5.1 3 3.3 6 33.3 1 7.	03 29 72 05 0.53); P 3 0 5 3 6 6 8 8 3 6 7 2 2 5 5 3 3 67 7 2 2 3 5 7 3 6 4 4 4 4 4 4 4	123.5 60.8 120.1 0% <u>No Sa</u> <u>Mean (Days)</u> 22 7 37 15.3 27 6 7.2 22.7 10	42.3 1 11 1 67.7 1 7 arcopenia <u>SD (Days</u> 14.3 55 8.4 21.1 8.3 20.4 21.5 8.3 20.4 21.5 20.4 21.5 20.4 21.5 20.4 21.5 20.4 21.5 20.4 21.5 20.4 21.5 20.4 21.5 21.5 21.5 21.5 21.5 21.5 21.5 21.5	43 11 3 20 39 10 39 10 5 18: 4 18: 1 10: 4 17: 9 7: 2 11: 5 12: 3 29: 138: 138: 138: 138: 138: 138: 138: 138: 138: 138: 139: 140: 139: 140: 140: 150: 1	6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 1 15.1% 7 21.0% 0 2.6% 4 15.7% 8 100.0%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [+10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% C1[ 4.00 [+0.03, 0.50 [+0.48, -8.00 [+20.25, 4.10 [0.75, 5.40 [+2.97,1] -2.00 [+3.5, 2.10 [0.91, 1.00 [+.21, 1.00 [+.21	ays] 2020 [] 2022 [] 2022 [] 2022 [] [] [] [] [] [] [] [] [] []	H-100 ar 17 18 19 20 20 20 22 23	-50 Favours Sarcopenia Mean D IV, Random,	Favours S bifference 95% CI (Day	50 sarcopenia	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, = 0.27 (P = 0.79) tal LOS Sa Mean [Days 2 7, 2 19, 32, 020 9, 31, 1 0; Chi <sup>#</sup> = 22.29, effa	16.1 16.2 3 3 3 3 3 3 3 3 3 3 4 5 3 3 3 3 3 3 3 3 3 3 3 3 3	03 29 72 05 0.53); P 8 8 1 3 6 6 3 3 6 7 3 8 8 8 1 3 6 6 3 3 6 7 3 8 7 7 2 2 3 5 7 3 8 7 3 8 8 1 3 6 7 2 9 72	123.5 60.8 120.1 = 0% <u>No Sa Mean (Days)</u> 22 7 7 7 15.3 27 6 7.2 22.7 10	42.3 1 11 1 67.7 1 7 rrcopenia SD [Days 14.4 5; 8.4 21.3 21.3 21.3 21.3 21.3 21.3 21.3 21.3	43 11 3 20 39 10 39 10 39 10 5 18: 4 18: 1 10: 4 17: 9 7: 5 12: 3 29: 138:	6.0% 8.2% 3.7% 00.0% 00.0% 1 Weight 5 8.6% 0 22.1% 3 1.4% 5 10.8% 3 2.7% 1 15.1% 7 21.0% 0 2.6% 4 15.7% 8 100.0%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [+0.3], 0.50 [+0.46, -8.00 [+20.25, 4.10 [+0.75, 5.40 [+2.97, 1] -2.00 [+3.35, 2.10 [10.91, 8.90 [0.29, 1] 1.00 [+1.21, 1.47 [=0.00, 2]	<ul> <li>ays] 2020</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>2023</li> <li>303</li> <li>2020</li> <li>2022</li> <li>31</li> <li>2024</li> <li>2024</li> <li>2025</li> <li>2024</li> <li>2026</li> <li>2027</li>     &lt;</ul>	Ar -100 ar 17 18 19 19 20 20 20 22 23	-50 ( Favours Sarcopenia IV, Random,	Favours S Difference 95% CI (Day	50 iarcopenia rs]	100
10.9     129.5     129.5     10.00; Chi≇ = 3.16,     = 0.27 (P = 0.79)     tal LOS     Sa     Mean [Days         2         2         7;         2         2         19         32     020 9,         31,     1     0; Chi₹ = 22.29, df =     1.95 (P = 0.05)	16.1 16.2 3 3 3 3 5 5 5 5 5 5 5 5 1 4 3 0.1 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); I <sup>2</sup> = 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	123.5 60.8 120.1 0% <u>Mean (Days)</u> 7 7 37 15.3 27 6 7.2 22.7 10	42.3 1 11 1 67.7 1 7 so (Days 50 (Days 14.4 8.4 21.4 8.4 21.4 8.4 21.4 20.4 21.4 20.4 21.4 21.4 21.4 21.4 21.4 21.4 21.4 21	43 11 3 20 39 10 39 10 5 18 5 18 4 18 1 18 1 18 5 7 2 11 5 7 1 2 1 3 29 138	6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 3 2.2% 3 2.2% 1 15.1% 7 21.0% 8 100.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [D 4.00 [-00.3, 0.50 [-0.46, -8.00 [-20.25, 4.10 [0.71, 5.40 [-2.97, 1 -2.00 [+3.35, 2.10 [0.91, 8.90 [0.29, 1 1.00 [-1.21, 1.47 [-0.00, 1	ays Ye ays Ye 0.03 20 0.03	ar 17 18 19 19 20 20 22 22 23	-50 Favours Sarcopenia IV, Random, 	Favours S bifference 95% CI (Day	50 iarcopenia rs]	100 50
60.9 129.5 0.00; Chi <sup>µ</sup> = 3.16, ( = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 19, 32, 020 9, 31, 0; Chi <sup>µ</sup> = 22.29, df = 1.95 (P = 0.05) S	5 16.1 16.1 16.2 3 3 3 5 5 5 5 5 5 5 5 5 5 5 2 4 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); P = 0.53); P = 0.53); P =	123.5 60.8 120.1 0% <u>Mean (Days)</u> 22 7 7 37 15.3 27 6 7.2 22.7 10	42.3 1 11 1 67.7 1 7 srcopenia 50 [Days 144 5 8.0 201 144 5 8.1 144 144 5 7	43 11 3 20 39 10 39 10 39 10 4 18 1 100 4 17 9 14 5 7 2 11 5 7 12 138	6.0% 8.2% 3.7% 5.00.0% 5.08% 0.221% 5.10.8% 1.151% 7.21.0% 8.100.0%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-0.03, 0.50 [-0.435, 2.10 [0.91, 8.90 [0.29, 1 1.00 [-1.21, 1.47 [-0.00, 7]	ays] Yee 0.03] 2022 3] 4] 4] 4] 4] 4] 4] 4] 4] 4] 4	Ar -100 ar 17 18 19 19 19 20 20 20 20 20 -50	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia	Favours S Difference 95% CI (Day 0 0 Favours N	50 sarcopenia rs) 25 to Sarcoper	100 50
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16; ( = 0.27 (P = 0.79) tal LOS Mean (Days 2 7, 2 19, 32, 020 9, 31, 10; Chi <sup>#</sup> = 22.29, df = 1.95 (P = 0.05) S	5 16.1 16.1 68.2 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); P : 3 1 Total 8 81 3 6 1 3 5 7 2 3 5 7 2 4 4 4 4 4 5 8 8 1 3 6 1 7 7 2 4 4 4 4 4 4 5 5 8 1 8 1 1 1 1 1 1 1 1 1 1 1 1 1	123.5 60.8 120.1 20.1 20% Mean [Days] 22 7 7 37 15.3 27 15.3 27 15.3 27 15.3 27 10 1%	42.3 1 11 1 67.7 1 7 strcopenia 5D [Days 14.4 5 5 8.0 20.5 20.5 20.5 20.5 20.5 20.5 20.5 20	43 11 3 20 39 10 39 10 39 10 39 10 4 18 1 100 4 18 1 100 4 18 1 100 4 18 1 100 4 18 1 29 1 38 1 39 1 39 1 39 1 39 1 4 1 39 1 39 1 38 1 38	6.0% 6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 3 1.4% 5 10.8% 3 2.7% 1 15.1% 7 21.0% 8 100.0% 8 100.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [[ 4.00 [-0.3] 0.50 [-0.46, -8.00 [-20.25, 4.10 [0.75, 5.40 [-2.87, 1 -2.00 [+3.35, 2.10 [0.91, 8.90 [0.29, 1 1.00 [-1.21, 1.47 [-0.00, 3 0.50 [-0.46, -1] 0.50 [-1, -1] 0.51 [-1, -1] 0.51 [-1, -1] 0.52 [-3.31, 4.3]	<ul> <li>ays) Ye</li> <li>ays) Ye</li> <li>ays) Ye</li> <li>ays) Joint Comparison</li> <li>ays) Ye</li> <li>ays</li></ul>	F-100 ar 17 18 19 19 20 20 20 20 22 23	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia	Favours S httlerence 95% CI (Day	50 sarcopenia rs] 25 Io Sarcoper	100 50
60.9 129.5 0.00; Chi <sup>µ</sup> = 3.16, ( = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 19, 32, 020 9, 31, 195 (P = 0.05) Sarcopy Mean Si	5 16.1 16.1 16.2 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); F : 05 0.53); F : 05 05 05 05 05 05 05 05 05 05 05 05 05	123.5 60.8 120.1 0% Mean [Days] 222 7 37 15.3 27 6 7.2 22.7 10 3%	42.3 1 11 1 17 7 7 30 [Desystant 50 [Desystant 144	43 11 3 20 39 10 39 10 39 10 39 10 4 18 1 100 4 18 1 100 4 18 1 100 4 18 1 100 4 18 1 100 4 18 1 100 1 29 1 38 M M M M	6.0% 6.0% 8.2% 3.7% 00.0% 1 Weight 5 8.6% 0 221% 5 8.6% 0 221% 1 151% 1 151% 8 100.0% 8 100.0%	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.34 Mean Difference N, Random, 95% CI [0 4.00 [-0.03, 0.50 [-0.46, -8.00 [-20.25, 4.10 [0.75, 5.40 [-2.87, 1 -2.00 [-4.35, 2.10 [0.91, 1.00 [-1.21, 1.47 [-0.00, 3 erence n, 95% CI Year	<ul> <li>ays] Yee</li> <li>ays] Yee</li> <li>0.03 20</li> <li>4.61 20</li> <li>2.51 20</li> <li>2.61 20</li> <li>2.71 20</li> <li>2.61 20</li> <li>2.71 20</li> <li>2.61 20</li></ul>	ar -100 -100 -100 -100 -100 -100 -100 -10	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differen IV, Random, 95	Favours S State of the second	50 sarcopenia rs] 25 to Sarcoper	100 50
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, ( 129.5	5 5 16.1 16.2 3 3 3 3 4 5 5 2 4 1 5 5 2 4 1 5 3 3 3 3 5 3 3 3 5 3 3 3 5 3 3 3 5 3 3 3 5 5 5 3 3 3 5 5 5 5 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); P : 0 0 0 0 0 0 0 0 0 0 0 0 0	123.5 60.8 120.1 0% 0% Mean (Days) 22 7 37 15.3 27 6 7.2 22.7 10 3% 1%	42.3 1 11 1 167.7 1 7 143.5 143.5 143.5 8.0 20.1 20	43 11 3 20 39 1( 39 1( 1 Tota 5 18: 4 18: 1 10: 9 14: 5 7: 2 11: 5 12: 1 38: M htt IV 36	6.0% 8.2% 3.7% 00.0% 1 Weighth 5 8.6% 0 22.1% 3 1.4% 1 51.0% 3 2.7% 3 2.7% 8 100.0% 4 15.7% 8 100.0% Hean Difff Randor 0.20 F0 0.20 F0 0.2	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CII 4.00 [+20.25, 4.10 [0.75, 5.40 [+2.97,1] 1.00 [+1.21, 1.47 [-0.00, ] erence m, 95% CI Year .63, 1.03] 2020	<ul> <li>ays) Yee</li> <li>ays) Yee</li> <li>0.031 20</li> <li>1.461 20</li> <li>1.451 20&lt;</li></ul>	ar 177 18 19 20 20 22 23 -50	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differer IV, Random, 95	Favours S Favours S Sty CI [Day B Favours N Ce Sty CI	50 sarcopenia rs] 25 to Sarcoper	100
60.9 129.5 2.0.0; Chi <sup>µ</sup> = 3.16, i = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 2 19, 32, 020 9, 1.95 (P = 0.05) Sarcopy Mean Si 0 3 2, 2, 9 4	16.1 16.1 16.2 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 005 1.53); F = 9 8 8 13 6 05 1.53); F = 9 8 8 13 6 73 8 43 7 2 8 43 7 7 8 43 7 7 8 8 13 5 8 14 15 15 15 15 15 15 15 15 15 15	123.5 60.8 120.1 0% Mean (Days) 7 7 7 7 7 7 7 7 7 7 7 7 7	42.3 1 11 1 11 1 7 rrcopenia <u>SD[Days</u> 14.4 5 8 21.1 8 21.1 8 21.2 20.	43 11 3 20 39 10 39 10 39 10 39 10 4 188 4 188 4 188 4 188 4 188 4 188 4 188 5 7 5 12 3 29 1388 MM t IV % 6	6.0% 6.0% 8.2% 3.7% 5.00% 5.00% 5.00% 3.1.4% 5.108% 3.2.7% 4.15.7% 8.100.0% 6.00% 6.00% 6.00% 6.0%	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [D 4.00 [-003, 0.50 [-0.46, -8.00 [-20.25, 4.10 [0.75, 5.40 [-2.97, 1 -2.00 [-4.35, 2.10 [0.91, 8.90 [0.29, 1 1.00 [-1.21, 1.47 [-0.00, 2 erence m, 95% CI Year 6.3, 1.03] 2020	8] 2020 1] 2022 2022 3] avrs] Ye 8.03] 20 4.6] 20 4.6] 20 4.6] 20 7.45] 20 7.45] 20 2.9] 20 7.45] 20 2.9] 2	ar 17 18 19 20 20 20 20 20 20 20 20 20 20 20 20 20	-50 Favours Sarcopenia IV, Random, IV, Random, -25 Favours Sarcopenia Mean Differen IV, Random, 95	Favours S Prevours S Prevours N Prevours N Prevours N Prevours N Prevours N	50 isarcopenia rs] 25 io Sarcoper	100
60.9 129.5 10.00; Chi <sup>p</sup> = 3.16; 129.5 1	5 5 16.1 16.1 68.2 3 3 3 5 5 5 5 5 5 5 5 5 5 5 2 4 3 3 3 5 5 5 5 5 5 5 2 4 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0,53); I <sup>2</sup> : 1 1 1 1 1 1 1 1 1 1 1 1 1	123.5 60.8 120.1 20% Mean [Days] 227 7 37 15.3 27 6 7.2 22.7 10 3% Arcopenia SD Tota 3.9 22 2 14 2.9 12	42.3 1 11 1 167.7 1 7 30 [Days 50 [Days 144.4 20.1 5 8. 20.3 21. 20.3 21. 20.3 21. 20.3 21. 20.3 21. 20.5	43 11 3 20 39 10 39 10 5 18: 5 18: 5 18: 4 18: 1 18: 1 18: 1 18: 1 18: 1 18: 1 18: 1 18: 1 18: 1 19: 1 19: 19	6.0% 6.0% 8.2% 3.7% 3.7% 3.7% 5.0% 5.0% 5.0% 1.151% 6.000% 6.000% 6.000% 6.000% 6.000% 6.000% 6.000% 6.00% 6.0% 6	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [0 4.00 [-02.25, 4.10 [0.75, 5.40 [-22.25, 4.10 [0.75, 5.40 [-247, 1 -2.00 [-4.35, 2.10 [0.91, 1.00 [-1.21, 1.47 [-0.00, 7 1.00 [-1.21, 1.47 [-0.00, 7 1.00 [-1.21, 1.47 [-0.00, 7 1.00 [-2, 23] 0.32 (-2, 23) 2020 0.32, 2.23] 2020 0.32, 2.23] 2020	<ul> <li>ays) 2020</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>2022</li> <li>3]</li> <li>ays) Yee</li> <li>a031 20</li> <li>a031 20</li> <li>a032 20</li> <li>a0445 20</li> <li>a245 20</li> <li>a245 20</li> <li>a249 20</li> <li>a241 20</li> <li>a241 20</li> <li>a241 20</li> <li>a241 20</li> <li>a241 20</li> <li>a321 20</li> <li>a445 20<!--</td--><td>ar 100 177 18 19 19 20 20 20 22 22 23</td><td>-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differen IV, Random, 95</td><td>Favours S State CI</td><td>50 sarcopenia rs] 25 to Sarcoper</td><td>100</td></li></ul>	ar 100 177 18 19 19 20 20 20 22 22 23	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differen IV, Random, 95	Favours S State CI	50 sarcopenia rs] 25 to Sarcoper	100
60.9 129.5 0.00; Chi <sup>#</sup> = 3.16, ( = 0.27 (P = 0.79) tal LOS Mean [Days 7, 7 2 19, 32, 020 9, 31, 1 0; Chi <sup>#</sup> = 22.29, df= 1.95 (P = 0.05) OS Sarcopp Mean Si 0 3 2.2, 2.9 4, 2 2.5 2.2, 4 3. (P = 0.25) (P	3           16.1           68.2           3           if = 4 (P = (           stf = 3 (           stf = 3 (           stf = 4 (P = (           stf = 4 (           stf = 3 (           stf = 4 (           stf = 3 (           st = 3 (	0.3 29 72 05 0.53); I <sup>2</sup> : 1 1 1 1 1 1 1 1 1 1 1 1 1	123.5 60.8 120.1 120	42.3 1 11 1 11 1 167.7 1 7 7 144 8 10 17 14 8 10 14 1 1 1 1 1 1 1 1 1 1 1 1 1	43 11 3 20 39 10 <u>39 10</u> <u>39 10</u> <u>59 50 500000000000000000000000000000000</u>	6.0% 6.0% 8.2% 3.7% 00.0% 1 Weighth 5 8.6% 0 221% 3 1.4% 7 21.0% 0 22.6% 4 15.7% 8 100.0% 15.1% 8 100.0% 15.5% 1	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CII 4.00 [-20.25, 4.10 [0.75, 5.40 [-20.71, 1.00 [-1.21, 1.00 [-1.21, 1.47 [-0.00; 3.1.03] 2020 0.33, 1.03] 2022 1.1, 2.11] 2023	<ul> <li>ays] 20202</li> <li>20227</li> <li>2022</li> <li>2022</li> <li>3]</li> <li>ays] Ye</li> <li>ays] Ye</li> <li>ays] 2022</li> <li>ays] 2022&lt;</li></ul>	4 -100 -100 -100 -100 -100 -100 -100 -50	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differet IV, Random, 95	Favours S Favours S 95% CI [Day a Favours N nce	50 sarcopenia rs]	100
60.9 129.5 0.00; Chi <sup>p</sup> = 3.16, ( = 0.27 (P = 0.79) tal LOS Mean [Days 7, 7, 19, 020 9, 31, 0; Chi <sup>p</sup> = 22.29, df- 1.95 (P = 0.05) OS Sarcopy Mean Si 0 3 2.2 2.9 4, 2 2.5 2.2 4 3.	16.1 16.1 16.2 3 3 3 3 5 5 5 2 4 3 3 3 5 5 2 4 3 3 3 5 2 4 3 3 3 5 2 4 3 3 3 5 5 5 2 4 4 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	03 29 72 05 0.53); F 2 3 6 6 3 3 6 7 3 6 8 4 3 6 7 3 8 4 3 5 7 8 4 4 4 ; F = 6 4 4 3 5 8 8 4 3 7 2 4 4 4 ; F 2 8 8 1 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 2 3 5 7 3 6 7 3 8 8 4 3 3 7 7 2 3 5 7 3 8 8 4 3 3 7 7 2 3 5 7 8 8 8 8 8 7 7 2 3 5 7 8 8 8 8 8 7 7 2 8 8 8 8 8 8 8 8 8 7 7 2 8 8 8 8	123.5 60.8 120.1 20% Mean [Days] 22 27 37 15.3 27 6 7.2 22.7 10 % spl Totage Spl Totage 3.9 22 2 1.5 29 78	42.3 1 11 1 11 1 167.7 1 7 rcopenia 50 [Days 144. 21.1 8 20.2 5 8 8 8 8 21.1 20.2 5 8 8 8 8 8 14 14 15 10 14 15 10 14 15 10 15 15 15 15 15 15 15 15 15 15	43 11 3 20 39 10 39 10 39 10 39 10 39 10 4 17 5 12 1 32 1 38 M ht IV % % % %	6.0% 6.0% 8.2% 3.7% 00.0% 1 Weight 0 221% 3 1.4% 5 8.6% 0 221% 3 1.4% 7 21.0% 0 2.2% 4 15.7% 8 100.0% 1.0% 1.0% 0.020 [0 1.00 [0 0.50 [0	3.50 [+12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI 4.00 [+20.25, 4.10 [0.75, 5.40 [+20.7], 1.00 [+1.21, 1.00 [+1.21, 1.47 [-0.00; 3.3, 1.03] 2020 0.32, 2.33 2020 0.33, 1.33] 2022 1.1, 2.11] 2023 1.3, 1.07]	a) 2020 [] 2022 [] 2022 [] 2022 [] avs1 // avs1 //	ar 17 18 19 20 20 20 20 20 20 20 20 20 20 20 20 20	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differen IV, Random, 95	Favours S Favours S 95% CI [Day Favours N A Favours N	50 sarcopenia rs] 25 to Sarcoper	100
60.9 129.5 10.00; Chi <sup>#</sup> = 3.16, = 0.27 (P = 0.79) tal LOS Mean [Days 2 7, 2 2 7, 2 19, 32, 020 9, 31, 1 0; Chi <sup>#</sup> = 22.29, df = 1.95 (P = 0.05) OS Sarcop Mean Si 2 .2, 2, 4 .3 = 0.00; Chi <sup>#</sup> = 2	senia D Total P Tot	0.3 29 72 05 0.53); P= 0 0 0 0 0 0 0 0 0 0 0 0 0	123.5 60.8 120.1 120	42.3 1 11 1 11 1 67.7 1 7 143 5 143 14 14 15 100.0 14 15 100.0	43 43 11 3 20 39 10 39 10 39 10 5 18 4 18 1 100 5 18 4 18 1 100 1 3 2 9 1 4 1 5 12 1 3 2 9 1 3 8 M M M M % % % % %	6.0% 8.2% 8.2% 3.7% 00.0% 1.0% 1.4% 5.86% 3.27% 3.1.4% 5.86% 3.27% 3.1.4% 5.86% 3.27% 3.1.4% 5.86% 3.27% 3.1.4% 5.86% 3.2.5% 4.15.7% 8.100.0% 0.020+0 1.00.0% 0.020+0 1.00.0% 0.020+0 0.020+0 1.00.0% 0.020+0 0.050+0 0.020+0	3.50 [-12.19, 19.1] 0.10 [-6.11, 6.3 9.40 [-10.47, 29.2 0.52 [-3.31, 4.3] Mean Difference IV, Random, 95% CI [D 4.00 [-00.3, 0.50 [-0.46, -8.00 [-20.25, 4.00 [-20.25, 4.00 [-20.25, 3.00 [-20.25, 4.00 [-20.25, 3.00 [-20.25, 1.00 [-20.25, 3.00 [-20.25, 1.00 [-20	ay c 202 ay c 2022 ay c 2022 a	r 100 17 18 19 19 20 20 20 20 20 20 20 20 20 20 20 20 20	-50 Favours Sarcopenia IV, Random, -25 Favours Sarcopenia Mean Differer IV, Random, 95	Afference 95% CI [Day 0 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7	50 sarcopenia rs] 25 to Sarcoper	100 50
	Mean [Min 38 39 3020 3244. 371. 19 21 00; Chi <sup>2</sup> = 1.91, df = 00; Chi <sup>2</sup> = 1.91, df = 00; Chi <sup>2</sup> = 0.96) me 5 Mean [Mi 10 11 2020 112: 92 11 2020 112: 92 11 2020 112: 92 11 2020 112: 92 11 2020 112: 92 11 2020 12 11 2020 12 12 12 12 12 12 12 12 12 12	Mean [Min]         SD [Min]           388         102           1020         324.9         138.3           371.3         119         193         30.4           215         40.7         215         40.7           00; Chi#=1.91, df = 4 (P = 0.7!         :0.05 (P = 0.96)         500; Chi#=1.91, df = 4 (P = 0.7!           Mean [Min]         SD [Min]         SD [Min]         105         33.1           184.4         67.1         105         33.1         177.5         79.1           192.0         112.28         56.         92.4         21.1         192.75.6         62.6         61.           .00; Chi#= 3.09, df = 8 (P = 0.9)         62         61.         .00; Chi#= 0.25)         70         50.25.           DC         Sarcopenia         Mean [Min] SD [Min] To         79.5         29.7         69         23.5           40.7         79.5         29.7         50.7	Mean [Min]         SD [Min]         Total           388         102         35           1020         324.9         138.3         43           371.3         119         72         193.3         30.4         29           215         40.7         44         223         215         40.7         44           200, Chi² = 1.91, df = 4 (P = 0.75); P = 09         505 (P = 0.96)         505 (P = 0.96)         500         105         33.5         61         105         33.5         61         105         33.5         61         105         33.5         61         105         33.5         61         105         33.5         61         105         33.5         61         105         33.5         61         105         34.5         61         105         34.5         61         105         34.5         61         105         34.5         62         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5         64         61.5	Mean [Min]         SD [Min]         Total         Mean [Min]           388         102         35         378           1020         324.9         138.3         43         349.4           371.3         119         72         358.1           193         30.4         29         195.5           215         40.7         44         214           223           200; Chi² = 1.91, df = 4 (P = 0.75); P = 0%           : 0.05 (P = 0.96)         50         175.5         61         173.2           Sarcopenia         No Sa           Mean [Min]         SD [Min]         Total Mean [Min]           Mean [Min]         SD [Min]         Total Mean [Min]           106         33.5         60         103.5           105         37.1         67         122.8           119         19.8         73         116           2020         112.28         56.9         43         104.53           203         24.2         21.6         29         90.2           182         75.2         72         180.4           62         61.5<	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]           388         102         35         378         109           1020         324.9         138.3         43         349.4         128.8           371.1         119         72         358.1         138.9         193.30.4         29         195.5         40.8           215         40.7         44         214         40           223           00; Chi#=1.91, df=4 (P=0.75); P=0%         :         0.05 (P=0.96)           TCE         Sarcopenia         No Sarcopenia         No Sarcopenia           Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]           184.4         67.5         81         172.6         68.4           105         37.1         67         123.9         48.4           119         19.8         73         116         20.2           2020         112.28         59.9         43         104.53         49.4           92.4         21.6         29         90.2         14.4         62.5         61.5           00; Chi#=3.09, df = 8 (P=0.93); P=0%         532         00.2 <t< td=""><td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total           388         102         35         378         109         103           1020         324.9         138.3         43         349.4         128.8         117           371.3         119         72         355.1         138.9         120         193         30.4         29         195.5         40.8         111           215         40.7         44         214         40         294           223         745         00; Chi²=1.91, df=4 (P=0.75); P=0%         50 (Min)         Total         Mean (Min)         SO (Min)         Total         105         33.5         60         103.5         37         16           105         33.5         60         103.5         37         16         17.72         40.2         16           107.5         35.5         60         103.5         37         16         12.6         84.4         11           119         37.1         67         12.6         84.4         11         13.2         43.6         17           119         19.8         73         116         20.7         116</td></t<> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight           388         102         35         378         109         103         4.7%           1020         324.9         138.3         43         349.4         128.8         117         3.3%           311.3         119         72         358.1         138.9         120         5.4%           193         30.4         29         195.5         40.8         111         41.5%           215         40.7         44         214         40         294         45.1%           C23         745         100.0%           00; ChiP=1.91, df=4 (P=0.75); P=0%         :         0.05 GP=0.96)           Pme         Sarcopenia         No Sarcopenia         Weight           105         33.5         60         103.5         37         100         14.3%           119         19.3         7.1         67         12.0%         14.3         24           120         5.17.6         68.4         113         24%         12.0%         14.3         21.0%         14.3         21.0%         14.3         21.0%         14.3</td> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]           388         102         35         378         109         103         4.7%         10.00 [-29.81, 49.8           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [-71.97, 22.9           371.3         119         72         358.1         138.9         120         5.4%         13.20 [-23.86, 50.2           193         30.4         29         195.5         40.8         111         41.5%         -25.0 [-15.92, 10.9           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.8           Vision 100%         -0.21 [-8.85, 8.4           00; Chi"=1.91, df=4 (P=0.75); P=0%         -0.21 [-8.85, 8.4         100; S0 [Min]         Total         Mean Difference           Mean [Min]         S0 [Min]         Total         Mean Difference         Mean Difference           105; GP=0.96)         37.1         67         12.9         4.3.6         175         1.19.2         1.50, 18.3         1.50, 18.3         1.50, 18.3         1.50, 18.3         1</td> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% C1 [Min]         Year           388         102         35         378         109         103         4.7%         10.00 [29.81, 48.81]         2019           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [71.97, 22.97]         2020         371.3         119         72         258.1         138.9         120         5.4%         13.20 [23.85, 60.20]         2022         215         40.7         44         214         40         294         45.1%         1.00 [11.87, 13.87]         2023           CLOP 1.91, df = 4 (P = 0.75); P = 0%           total         Mean 200%           Mean 10/ff rence           Mean 10/f rence           Mean 10/f rence         Mean 10/f renc</td> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Mean [Min]         Vear           388         102         35         378         109         103         4.7%         10.00.[-29.81, 49.81]         2019           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [-71.97, 22.97]         2000           371.3         119         72         358.1         138.9         120.5         5.4%         13.20 [-23.86, 20.26]         2022           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.87]         2023           Cast of the end of the end</td> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Mean [Min]         SD [Min]</td> <td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]         Year         IV, Random, 95% CI [Min]           388         102         35         378         109         103         4.7%         10.00 [29.81, 49.81]         2019           3010         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [71.97, 22.97]         2020           193         30.4         29         195.5         40.8         111         41.5%         -250 [15.92, 10.92]         2022           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.87]         2023           00, Chi" = 1.91, df = 4 (P = 0.75); P = 0%         .         <t< td=""><td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]         Year         IV, Random, 95% CI [Min]           1020         324.9         138.3         43         349.4         128.6         117         3.3%         -24.50 [F1.97, 22.97]         2020         117         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         13.3%         -24.50 [F1.97, 22.97]         2020         11.2         11.2         11.2         11.2         11.2         12.2         13.2         12.2         12.2         13.2         12.2         <td< td=""></td<></td></t<></td>	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total           388         102         35         378         109         103           1020         324.9         138.3         43         349.4         128.8         117           371.3         119         72         355.1         138.9         120         193         30.4         29         195.5         40.8         111           215         40.7         44         214         40         294           223         745         00; Chi²=1.91, df=4 (P=0.75); P=0%         50 (Min)         Total         Mean (Min)         SO (Min)         Total         105         33.5         60         103.5         37         16           105         33.5         60         103.5         37         16         17.72         40.2         16           107.5         35.5         60         103.5         37         16         12.6         84.4         11           119         37.1         67         12.6         84.4         11         13.2         43.6         17           119         19.8         73         116         20.7         116	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight           388         102         35         378         109         103         4.7%           1020         324.9         138.3         43         349.4         128.8         117         3.3%           311.3         119         72         358.1         138.9         120         5.4%           193         30.4         29         195.5         40.8         111         41.5%           215         40.7         44         214         40         294         45.1%           C23         745         100.0%           00; ChiP=1.91, df=4 (P=0.75); P=0%         :         0.05 GP=0.96)           Pme         Sarcopenia         No Sarcopenia         Weight           105         33.5         60         103.5         37         100         14.3%           119         19.3         7.1         67         12.0%         14.3         24           120         5.17.6         68.4         113         24%         12.0%         14.3         21.0%         14.3         21.0%         14.3         21.0%         14.3	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]           388         102         35         378         109         103         4.7%         10.00 [-29.81, 49.8           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [-71.97, 22.9           371.3         119         72         358.1         138.9         120         5.4%         13.20 [-23.86, 50.2           193         30.4         29         195.5         40.8         111         41.5%         -25.0 [-15.92, 10.9           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.8           Vision 100%         -0.21 [-8.85, 8.4           00; Chi"=1.91, df=4 (P=0.75); P=0%         -0.21 [-8.85, 8.4         100; S0 [Min]         Total         Mean Difference           Mean [Min]         S0 [Min]         Total         Mean Difference         Mean Difference           105; GP=0.96)         37.1         67         12.9         4.3.6         175         1.19.2         1.50, 18.3         1.50, 18.3         1.50, 18.3         1.50, 18.3         1	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% C1 [Min]         Year           388         102         35         378         109         103         4.7%         10.00 [29.81, 48.81]         2019           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [71.97, 22.97]         2020         371.3         119         72         258.1         138.9         120         5.4%         13.20 [23.85, 60.20]         2022         215         40.7         44         214         40         294         45.1%         1.00 [11.87, 13.87]         2023           CLOP 1.91, df = 4 (P = 0.75); P = 0%           total         Mean 200%           Mean 10/ff rence           Mean 10/f rence           Mean 10/f rence         Mean 10/f renc	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Mean [Min]         Vear           388         102         35         378         109         103         4.7%         10.00.[-29.81, 49.81]         2019           1020         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [-71.97, 22.97]         2000           371.3         119         72         358.1         138.9         120.5         5.4%         13.20 [-23.86, 20.26]         2022           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.87]         2023           Cast of the end	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Mean [Min]         SD [Min]	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]         Year         IV, Random, 95% CI [Min]           388         102         35         378         109         103         4.7%         10.00 [29.81, 49.81]         2019           3010         324.9         138.3         43         349.4         128.8         117         3.3%         -24.50 [71.97, 22.97]         2020           193         30.4         29         195.5         40.8         111         41.5%         -250 [15.92, 10.92]         2022           215         40.7         44         214         40         294         45.1%         1.00 [-11.87, 13.87]         2023           00, Chi" = 1.91, df = 4 (P = 0.75); P = 0%         . <t< td=""><td>Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]         Year         IV, Random, 95% CI [Min]           1020         324.9         138.3         43         349.4         128.6         117         3.3%         -24.50 [F1.97, 22.97]         2020         117         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         13.3%         -24.50 [F1.97, 22.97]         2020         11.2         11.2         11.2         11.2         11.2         12.2         13.2         12.2         12.2         13.2         12.2         <td< td=""></td<></td></t<>	Mean [Min]         SD [Min]         Total         Mean [Min]         SD [Min]         Total         Weight         IV, Random, 95% CI [Min]         Year         IV, Random, 95% CI [Min]           1020         324.9         138.3         43         349.4         128.6         117         3.3%         -24.50 [F1.97, 22.97]         2020         117         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         3.3%         -24.50 [F1.97, 22.97]         2020         118.3         10.2         13.3%         -24.50 [F1.97, 22.97]         2020         11.2         11.2         11.2         11.2         11.2         12.2         13.2         12.2         12.2         13.2         12.2 <td< td=""></td<>

	Sarcopenia No Sarcopenia							Mean Difference		Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI		
Kiryia et al. 2020	27.6	70.8	63	15.1	27.4	143	0.1%	12.50 [-5.55, 30.55]	2020			
Dh et. 2020	14	3	73	12	2	71	63.2%	2.00 [1.17, 2.83]	2020			
/uenyongchaiwat et al. 2020	14.5	4.7	43	12.1	4.9	117	15.8%	2.40 [0.74, 4.06]	2020	+		
Shibasaki et al. 2022	23.2	4.8	72	20.9	5.2	120	20.8%	2.30 [0.85, 3.75]	2022	-		
otal (95% CI)			251			451	100.0%	2.14 [1.48, 2.80]		•		
Heterogeneity: Tau <sup>2</sup> = 0.00; Ch	i² = 1.52	df = 3	(P=0	.68); I <sup>2</sup> =	0%				_			
fest for overall effect Z = 6.35	(P < 0.00	0001)								Favours Sarcopenia Favours No Sarcopenia		

**Figure 3.** Forest Plots for the secondary outcomes focused on timing. (**A**) Overall surgical time; (**B**) CBP time; (**C**) CC time; (**D**) Hospital LOS; (**E**) ICU LOS; (**F**) Intubation time. References [12–18,20–23].

### 3.3.6. ICU LOS

Sarcopenic patients were compared with non-sarcopenic patients, with four studies reporting on ICU LOS (Figure 3E). The overall MD for ICU LOS showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: MD: 0.60; 95% CI: 0.13 to 1.07; p = 0.01). There was evidence of no heterogeneity among studies reporting on ICU LOS.

#### 3.3.7. Intubation Time

Sarcopenic patients were compared with non-sarcopenic patients, with four studies reporting on intubation time (Figure 3F). The overall MD for intubation time showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: MD: 2.14; 95% CI: 1.48 to 2.80; p < 0.0001). There was evidence of no heterogeneity among studies reporting on intubation time.

#### 3.3.8. Postoperative Arrhythmia

Sarcopenic patients were compared with non-sarcopenic patients, with six studies reporting on postoperative arrhythmia (Figure 4A). The overall OR for postoperative arrhythmia showed no statistically significant difference (random-effects model: OR: 1.08; 95% CI: 0.64 to 1.81; p = 0.77). There was evidence of moderate heterogeneity among studies reporting on postoperative arrhythmia.

#### 3.3.9. Stroke

Sarcopenic patients were compared with non-sarcopenic patients, with six studies reporting on stroke (Figure 4B). The overall OR for stroke showed no statistically significant difference (random-effects model: OR: 1.55; 95% CI: 0.84 to 2.86; p = 0.16). There was evidence of no heterogeneity among studies reporting on stroke.

#### 3.3.10. Sternal Wound Infection

Sarcopenic patients were compared with non-sarcopenic patients, with six studies reporting on sternal wound infection (Figure 4C). The overall OR for sternal infection showed no statistically significant difference (random-effects model: OR: 1.76; 95% CI: 0.80 to 3.88; p = 0.16). There was evidence of no heterogeneity among studies reporting on sternal infection.

# 3.3.11. Postoperative Need for Dialysis

Sarcopenic patients were compared with non-sarcopenic patients, with five studies reporting on dialysis (Figure 4D). The overall OR for dialysis showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: OR: 2.87; 95% CI: 1.19 to 6.94; p = 0.02). There was evidence of no heterogeneity among studies reporting on dialysis.

# 3.3.12. Discharge to Care Home

Sarcopenic patients were compared with non-sarcopenic patients, with six studies reporting on care home discharge (Figure 4E). The overall OR for care home discharge showed a statistically significant difference favouring non-sarcopenic patients (random-effects model: OR: 1.92; 95% CI: 1.31 to 2.81; p < 0.001). There was evidence of no heterogeneity among studies reporting on care home discharge.

Total (95% CD

Heterogeneity: Tau<sup>2</sup> = 1.50; Chi<sup>2</sup> = 14.98, df = 7 (P = 0.04); i<sup>2</sup> = 53%

Test for overall effect Z = 2.76 (P = 0.006)

465

1317 100.0%

# A. Postoperative arrhythmia



**Figure 4.** Forest Plots for the secondary outcomes. **(A)** Postoperative arrhythmia; **(B)** Stroke; **(C)** Sternal wound infection; **(D)** Need for dialysis; **(E)** discharge to care home; **(F)** Sensitivity analysis: Hospital LOS. References [12–18,20–23].

-50

-25

50

25

Favours Sarcopenia Favours No Sarcopenia

1.96 (0.57, 3.34)

#### 3.4. Sensitivity Analysis: Hospital LOS

Sensitivity analysis was carried out for all outcomes, with all outcomes other than Hospital LOS showing no statistically different impact on heterogeneity. Sarcopenic patients were compared with non-sarcopenic patients, with eight studies reporting on hospital LOS (Figure 4F). The overall MD for Hospital LOS showed a statistically significant difference favouring non-sarcopenic patients when the study by Oh et al. was removed (random-effects model: MD: 1.96; 95% CI: 0.57 to 3.34; p = 0.005). There was evidence of moderate heterogeneity among studies reporting on Hospital LOS.

# 3.5. Risk of Bias across the Studies

The funnel plot analysis (Supplementary Figures S1–S9) disclosed no asymmetry around the axis for the outcomes, thus making publication bias related to all outcomes unlikely.

#### 4. Discussion

# 4.1. Sarcopenia and Mortality

The findings of our study demonstrate a significant difference in both early and late mortality between sarcopenic and non-sarcopenic patients undergoing cardiac surgery. These results are in line with the existing body of literature on the subject. Specifically, the OR for early mortality was 2.40 (95% CI: 1.44 to 3.99; p < 0.001), and for late mortality, it was 2.65 (95% CI: 1.57 to 4.48; p < 0.001). These results indicate that sarcopenic patients faced more than twice the risk of experiencing early mortality postoperatively compared to their non-sarcopenic counterparts. This elevated risk is likely attributed to the diminished physical reserve and heightened vulnerability to stressors, such as surgery, observed in sarcopenic patients [24].

Our findings align with the study by Englesbe et al., 2010 [25], which found sarcopenia to be a significant predictor of mortality in patients undergoing major elective general abdominal surgery and transplantation. The study reported an OR of 2.86, indicating that sarcopenic patients were nearly three times more likely to die than non-sarcopenic patients. Similarly, a systematic review and meta-analysis by Malietzis et al., 2016 [26] found that sarcopenia was associated with increased postoperative complications and mortality in patients undergoing gastrointestinal surgery.

Furthermore, the results of our study build upon the findings of Wayda et al., 2018 [27], supporting the independent association between socioeconomic status, as assessed by the Distressed Communities Index (DCI), and operative mortality following coronary artery bypass grafting (CABG). Wayda et al.'s study revealed that patients with low socioeconomic status (SES) based on the DCI had a 1.6-fold higher risk of postoperative mortality following CABG compared to patients with high SES. These findings suggest that socioeconomic factors, which might hypothetically influence the prevalence and impact of sarcopenia [28], also substantially influence patient outcomes.

The combined impact of sarcopenia on the overall mortality risk in surgical patients is noteworthy. Sarcopenia, often associated with aging, malnutrition, and physical inactivity, contributes to reduced muscle strength and poor physical performance [29], thereby elevating the risk of unfavourable postoperative outcomes. The presence of sarcopenia can exacerbate the challenges encountered by patients with low SES, who may already be at a higher risk of poor outcomes due to limited access to healthcare, poor nutrition, and higher stress levels.

# 4.2. Surgical Time

Our data showed no statistically significant difference in overall surgery time, CBP time, and CC time between sarcopenic and non-sarcopenic patients. This suggests that sarcopenia does not significantly prolong the duration of cardiac surgery. This is consistent with the findings of a study by Fukuda et al., 2016 [30], which found no significant difference

in operation times between sarcopenic and non-sarcopenic patients undergoing gastric cancer surgery.

With the exception of patients with sarcopenic obesity, surgical access is not influenced by sarcopenia, and the technical aspects of the procedure can be carried out seamlessly, especially when one does not encounter significant amounts of pre-pericardial or epicardial fat that is often seen in obese patients. However, it is worth noting that the lack of significant difference in surgical time does not negate the potential impact of sarcopenia on other surgical outcomes.

# 4.3. Infection Rates

Our data showed no statistically significant difference in the rate of sternal infection between sarcopenic and non-sarcopenic patients. This is an interesting finding, as some studies have suggested that sarcopenia may increase the risk of postoperative infections. For instance, a study by Lieffers et al., 2012 [31] found that sarcopenia was associated with a higher risk of infection in cancer patients. It is recognised that obesity is the main risk factor for surgical site infections such as sternal wound infections [32,33]. Unless there is sarcopenic obesity or an active hypercatabolic state, sternal closure and healing should not be negatively influenced in sarcopenic patients, which would have led to significantly higher wound complications against the non-sarcopenic counterparts. This discrepancy may be due to differences in patient populations, surgical procedures, and infection prevention measures, warranting further investigation.

# 4.4. Functional Outcomes

Our data showed statistically significant differences in several functional outcomes between sarcopenic and non-sarcopenic patients. Sarcopenic patients had a longer ICU length of stay, higher likelihood of requiring dialysis, higher rate of care home discharge, and longer intubation time. These findings suggest that sarcopenia can significantly impact patients' postoperative recovery and quality of life.

- (a) ICU Length of Stay: The longer ICU stay for sarcopenic patients may be due to their lower physiological reserve and increased vulnerability to complications. Sarcopenia, characterised by a loss of muscle mass and function, can lead to frailty, which is associated with a higher risk of adverse outcomes, including prolonged ICU stay. This is supported by a study by Moisey et al., 2013 [34], which found that sarcopenic patients had a longer ICU stay after emergency abdominal surgery.
- (b) Dialysis: The higher likelihood of requiring dialysis in sarcopenic patients probably relates to their increased risk of acute kidney injury (AKI) postoperatively. Sarcopenia may contribute to AKI through various mechanisms, including inflammatory pathway activation following chronic inflammation and increased susceptibility to nephrotoxic agents [35]. A study by Bang et al. [35] found that sarcopenia was an independent risk factor for AKI in patients undergoing abdominal aortic aneurysm surgery.
- (c) Care Home discharge: The higher rate of care home discharge for sarcopenic patients may reflect their poorer functional status and increased need for assistance with daily activities postoperatively. Sarcopenia is associated with physical disability and reduced independence, which may necessitate care home admission. This is consistent with a study by Landi et al., 2012 [36], which found that sarcopenic older adults were more likely to be institutionalised.
- (d) Intubation Time: The longer intubation time for sarcopenic patients may be due to their increased risk of respiratory complications. Sarcopenia can impair respiratory muscle function, leading to reduced lung volumes and ineffective cough, which can prolong the need for mechanical ventilation. A study by Puthucheary et al., 2013 [37] found that ICU-acquired weakness, which is often associated with sarcopenia, was a predictor of prolonged mechanical ventilation.

#### 4.5. Measurements of Sarcopenia in Clinical Practice

Sarcopenia is typically identified and measured using a combination of methods that assess muscle mass, muscle strength, and physical performance. The EWGSOP and the AWGS have provided guidelines for the diagnosis of sarcopenia, which include the use of these three parameters [5,6]. However, in the practical setting of cardiac surgery, where patients often undergo preoperative CT scans, these existing images can be utilised to assess sarcopenia, making it a practical and cost-effective approach. The most common method of assessing sarcopenia using CT scans is by measuring the cross-sectional skeletal muscle area (SMA, cm<sup>2</sup>) at the level of the third lumbar vertebra, which is highly correlated with total body muscle mass. Adjusting the SMA for height squared yields the Skeletal Muscle Index (SMI,  $cm^2/m^2$ ), a metric used to assess relative muscle mass. While the specific thresholds can vary, depending on age, body mass index (BMI), and definitions of sarcopenia, a commonly used threshold is an SMI less than 50–55 cm<sup>2</sup>/m<sup>2</sup> for men and less than  $35-40 \text{ cm}^2/\text{m}^2$  for women [38]. van der Werf et al. demonstrated a predicted 5th percentile SMI value (for all BMIs) of 36.9  $\text{cm}^2/\text{m}^2$  for men and 28.2  $\text{cm}^2/\text{m}^2$  for women in the age group of 70–79 years, indicating the extent and frequency of muscle mass loss in this age group [39]. Lastly, the psoas muscle has also been of particular interest as it can be easily visualised and measured on routine preoperative CT scans. The cross-sectional area of the psoas muscle has been used as a surrogate marker for total body muscle mass.

#### 4.6. Sarcopenia and Frailty

The interaction between sarcopenia and frailty is complex and multifaceted, and both conditions often coexist in older adults, making their assessment and management challenging. Sarcopenia, characterised by the loss of muscle mass and strength, and frailty, a state of increased vulnerability to stressors due to decreased physiological reserves, are both prevalent conditions in older adults [24]. A cross-sectional study conducted by Gingrich et al. (2019) found that 42% of older medical inpatients had sarcopenia and 33% were frail, with these conditions overlapping in 19% of patients [40]. This indicates a significant interaction between the two syndromes, suggesting they may share common etiological factors such as reduced food intake, inflammation, hormonal changes, increased energy requirements, and reduced physical activity.

While sarcopenia can be measured relatively directly through assessments of muscle mass and strength, frailty, due to its multifaceted nature, is more challenging to measure. Frailty encompasses a decline in function across multiple organ systems, leading to increased vulnerability to stressors [41]. Various frailty indices and scales have been developed, such as the Fried Frailty Index and the Frailty Phenotype, but these require comprehensive clinical assessments and may not be feasible in all settings [41]. Furthermore, there is no universally accepted definition or measurement for frailty, leading to variability in how it is assessed and interpreted in clinical and research settings.

#### 4.7. Recommendations for Optimising Cardiac Surgery Outcomes in Sarcopenic Patients

- 1. Preoperative identification of sarcopenia: Early identification of sarcopenia can allow for preoperative interventions to improve patient outcomes. This can be achieved through simple screening tools or more comprehensive assessments such as CT or MRI scans.
- Preoperative optimisation: Once sarcopenia is identified, preoperative optimisation strategies should be implemented. This could include nutritional supplementation, physical therapy, and exercise programs aimed at increasing muscle mass and strength.
- Risk stratification: Sarcopenic patients should be considered high-risk surgical candidates. This should be considered when planning the surgical approach and postoperative care.

- 4. Intraoperative care: Consideration should be given to minimizing operative time and blood loss, as sarcopenic patients may be more susceptible to intraoperative complications.
- 5. Postoperative rehabilitation: Early mobilisation and physical therapy should be initiated postoperatively to prevent further muscle loss and to promote recovery.
- 6. Nutritional support: Postoperative nutritional support should be provided to meet the increased protein and calorie needs of sarcopenic patients and to support muscle recovery.
- 7. Multidisciplinary approach: The care of sarcopenic patients should involve a multidisciplinary team, including surgeons, anaesthesiologists, dietitians, physical therapists, and geriatricians. This can ensure a comprehensive approach to the management of sarcopenia and its associated risks.
- 8. Patient education: Patients should be educated about the implications of sarcopenia and the steps they can take to improve their muscle health. This can empower patients to take an active role in their care and recovery.
- Research: Further research should be conducted to better understand the impact of sarcopenia on cardiac surgery outcomes and to develop effective interventions for this patient population.

# 5. Conclusions

In conclusion, this meta-analysis highlights the significant adverse impact of sarcopenia on patients undergoing cardiac surgery. Sarcopenic patients demonstrate higher early and late mortality rates, longer ICU stays, increased likelihood of requiring dialysis, higher rates of care home discharge, and longer intubation times. These findings underscore the importance of recognizing sarcopenia as a significant risk factor in cardiac surgery.

Our findings align with existing literature across various surgical fields, further emphasizing the universal relevance of sarcopenia in surgical outcomes. Despite the heterogeneity in some of the studies, the overall trend suggests a consistently negative impact of sarcopenia on postoperative outcomes. However, our study also revealed that sarcopenia did not significantly affect certain outcomes, such as surgical time and infection rates. This suggests that the influence of sarcopenia may be more pronounced in certain areas, and its impact may be modulated by other factors such as surgical technique, perioperative care, and the patient's overall health status. To optimize outcomes in sarcopenic patients, a comprehensive and multidisciplinary approach is recommended. This includes early identification and preoperative optimisation of sarcopenic patients, risk stratification, careful intraoperative management, postoperative rehabilitation, nutritional support, and patient education. Further research is needed to better understand the mechanisms underlying the impact of sarcopenia on surgical outcomes and to develop effective interventions.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12175573/s1, Figure S1: Overall Surgery Duration; Figure S2: CBP Time; Figure S3: CC Time; Figure S4: Hospital LOS; Figure S5: ICU LOS; Figure S6: In hospital mortality; Figure S7: Early mortality; Figure S8: Late mortality; Figure S9: Arrhythmia; Table S1: Continuous baseline characteristics of the included studies.

Author Contributions: Conceptualisation, A.A., A.A.R., M.K., D.A., T.A. and A.K.; methodology, A.A., A.A.R., M.K., D.A., T.A. and A.K.; software A.A., A.A.R., M.K., D.A., T.A. and A.K.; validation, A.A., A.A.R., M.K., D.A., T.A. and A.K.; formal analysis, A.A.R.; investigation, A.A., A.A.R., M.K., D.A., T.A. and A.K.; D.A., T.A. and A.K.; formal analysis, A.A.R.; investigation, A.A., A.A.R., M.K., D.A., T.A. and A.K.; D.A., T.A. and A.K.; formal analysis, A.A.R.; investigation, A.A., A.A.R., M.K., D.A., T.A. and A.K.; bit curation, A.A.R. and A.A.; writing—original draft preparation, A.A. and A.A.R.; writing—review and editing, A.A. and A.A.R.; visualisation, A.A.R.; supervision, D.A., T.A. and A.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Informed Consent Statement: Does not apply.

**Data Availability Statement:** All the data is available upon request from the corresponding author (A.K.).

Conflicts of Interest: The authors declare no conflict of interest.

# References

- 1. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **2019**, *48*, 16–31. [CrossRef]
- 2. Xia, L.; Zhao, R.; Wan, Q.; Wu, Y.; Zhou, Y.; Wang, Y.; Cui, Y.; Shen, X.; Wu, X. Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. *Cancer Med.* **2020**, *9*, 7964–7978. [CrossRef]
- He, N.; Zhang, Y.; Zhang, L.; Zhang, S.; Ye, H. Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview. *Front. Cardiovasc. Med.* 2021, *8*, 743710. [CrossRef]
- Pring, E.T.; Gould, L.E.; Malietzis, G.; Lung, P.; Bharal, M.; Fadodun, T.; Bassett, P.; Naghibi, M.; Taylor, C.; Drami, I.; et al. BiCyCLE NMES—Neuromuscular electrical stimulation in the perioperative treatment of sarcopenia and myosteatosis in advanced rectal cancer patients: Design and methodology of a phase II randomised controlled trial. *Trials* 2021, 22, 621. [CrossRef]
- Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.-P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [CrossRef] [PubMed]
- Chen, L.-K.; Woo, J.; Assantachai, P.; Auyeung, T.-W.; Chou, M.-Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J. Am. Med. Dir. Assoc.* 2020, 21, 300–307.e302. [CrossRef] [PubMed]
- Tang, T.-C.; Hwang, A.-C.; Liu, L.-K.; Lee, W.-J.; Chen, L.-Y.; Wu, Y.-H.; Huang, C.-Y.; Hung, C.-H.; Wang, C.-J.; Lin, M.-H.; et al. FNIH-defined Sarcopenia Predicts Adverse Outcomes Among Community-Dwelling Older People in Taiwan: Results From I-Lan Longitudinal Aging Study. J. Gerontol. Ser. A 2017, 73, 828–834. [CrossRef] [PubMed]
- 8. De Santo, L.S.; Moscariello, C.; Zebele, C. Implications of obesity in cardiac surgery: Pattern of referral, physiopathology, complications, prognosis. *J. Thorac. Dis.* **2018**, *10*, 4532–4539. [CrossRef] [PubMed]
- 9. Zhigalov, K.; Oliveira Sá, M.P.B.; Rad, A.A.; Vardanyan, R.; Goerdt, L.; Chrosch, T.; Zubarevich, A.; Wendt, D.; Pizanis, N.; Koch, A.; et al. The Impact of Obesity on Left Ventricular Assist Device Outcomes. *Medicina* **2020**, *56*, 556. [CrossRef]
- 10. Rothman, K.J. BMI-related errors in the measurement of obesity. Int. J. Obes. 2008, 32, S56–S59. [CrossRef]
- Zhang, X.; Xie, X.; Dou, Q.; Liu, C.; Zhang, W.; Yang, Y.; Deng, R.; Cheng, A.S.K. Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: A updated meta-analysis. *BMC Geriatr.* 2019, 19, 183. [CrossRef]
- 12. Shibasaki, I.; Ouchi, M.; Fukuda, T.; Tsuchiya, G.; Ogawa, H.; Takei, Y.; Tezuka, M.; Kanazawa, Y.; Katayanagi, S.; Nozawa, N.; et al. Effect of sarcopenia on hospital stay from post cardiac surgery to discharge. *IJC Heart Vasc.* **2022**, *39*, 101003. [CrossRef]
- Kondo, Y.; Suzuki, T.; Enomoto, M.; Takashima, N.; Kinoshita, T. Psoas muscle size, possible sarcopenia and frailty, and long-term survival in elderly patients after isolated surgical aortic valve replacement for aortic stenosis. *Indian J. Thorac. Cardiovasc. Surg.* 2022, *38*, 134–141. [CrossRef] [PubMed]
- Okamura, H.; Kimura, N.; Mieno, M.; Yuri, K.; Yamaguchi, A. Preoperative sarcopenia is associated with late mortality after off-pump coronary artery bypass grafting. *Eur. J. Cardio-Thorac. Surg.* 2020, 58, 121–129. [CrossRef] [PubMed]
- 15. Yuenyongchaiwat, K.; Kulchanarat, C.; Satdhabudha, O. Sarcopenia in open heart surgery patients: A cohort study. *Heliyon* **2020**, *6*, e05759. [CrossRef] [PubMed]
- Oh, J.; Song, I.-K.; Nam, J.-S.; Lee, S.-W.; Lee, E.-H.; Choi, I.-C. Sarcopenia as a prognostic factor for outcomes after isolated tricuspid valve surgery. J. Cardiol. 2020, 76, 585–592. [CrossRef]
- Kurumisawa, S.; Kawahito, K. The psoas muscle index as a predictor of long-term survival after cardiac surgery for hemodialysisdependent patients. J. Artif. Organs 2019, 22, 214–221. [CrossRef]
- Hawkins, R.B.; Mehaffey, J.H.; Charles, E.J.; Kern, J.A.; Lim, D.S.; Teman, N.R.; Ailawadi, G. Psoas Muscle Size Predicts Risk-Adjusted Outcomes After Surgical Aortic Valve Replacement. Ann. Thorac. Surg. 2018, 106, 39–45. [CrossRef]
- Yamashita, M.; Kamiya, K.; Matsunaga, A.; Kitamura, T.; Hamazaki, N.; Matsuzawa, R.; Nozaki, K.; Tanaka, S.; Nakamura, T.; Maekawa, E.; et al. Prognostic Value of Psoas Muscle Area and Density in Patients Who Undergo Cardiovascular Surgery. *Can. J. Cardiol.* 2017, 33, 1652–1659. [CrossRef]
- Ikeno, Y.; Koide, Y.; Abe, N.; Matsueda, T.; Izawa, N.; Yamazato, T.; Miyahara, S.; Nomura, Y.; Sato, S.; Takahashi, H.; et al. Impact of sarcopenia on the outcomes of elective total arch replacement in the elderly<sup>+</sup>. *Eur. J. Cardio-Thorac. Surg.* 2017, *51*, 1135–1141. [CrossRef]
- Teng, C.-H.; Chen, S.-Y.; Wei, Y.-C.; Hsu, R.-B.; Chi, N.-H.; Wang, S.-S.; Chen, Y.-S.; Chen, C.C.-H. Effects of sarcopenia on functional improvement over the first year after cardiac surgery: A cohort study. *Eur. J. Cardiovasc. Nurs.* 2019, *18*, 309–317. [CrossRef] [PubMed]
- Shen, Z.-L.; Liu, Z.; Zang, W.-F.; Zhang, P.; Zou, H.-B.; Dong, W.-X.; Chen, W.-H.; Yan, X.-L.; Yu, Z. Thoracic sarcopenia predicts clinical outcomes in patients undergoing coronary artery bypass grafting: A 6-year cohort study. *Asian J. Surg.* 2023, 46, 291–298. [CrossRef]

- Kiriya, Y.; Toshiaki, N.; Shibasaki, I.; Ogata, K.; Ogawa, H.; Takei, Y.; Tezuka, M.; Seki, M.; Kato, T.; Lefor, A.K.; et al. Sarcopenia assessed by the quantity and quality of skeletal muscle is a prognostic factor for patients undergoing cardiac surgery. *Surg. Today* 2020, *50*, 895–904. [CrossRef] [PubMed]
- 24. Papadopoulou, S.K. Sarcopenia: A Contemporary Health Problem among Older Adult Populations. *Nutrients* **2020**, *12*, 1293. [CrossRef] [PubMed]
- 25. Englesbe, M.J.; Patel, S.P.; He, K.; Lynch, R.J.; Schaubel, D.E.; Harbaugh, C.; Holcombe, S.A.; Wang, S.C.; Segev, D.L.; Sonnenday, C.J. Sarcopenia and Mortality after Liver Transplantation. *J. Am. Coll. Surg.* **2010**, *211*, 271–278. [CrossRef]
- Malietzis, G.; Currie, A.C.; Athanasiou, T.; Johns, N.; Anyamene, N.; Glynne-Jones, R.; Kennedy, R.H.; Fearon, K.C.H.; Jenkins, J.T. Influence of body composition profile on outcomes following colorectal cancer surgery. *Br. J. Surg.* 2016, 103, 572–580. [CrossRef]
- Wayda, B.; Clemons, A.; Givens, R.C.; Takeda, K.; Takayama, H.; Latif, F.; Restaino, S.; Naka, Y.; Farr, M.A.; Colombo, P.C.; et al. Socioeconomic Disparities in Adherence and Outcomes After Heart Transplant: A UNOS (United Network for Organ Sharing) Registry Analysis. *Circ. Heart Fail.* 2018, 11, e004173. [CrossRef]
- Swan, L.; Warters, A.; O'Sullivan, M. Socioeconomic Inequality and Risk of Sarcopenia in Community-Dwelling Older Adults. *Clin. Interv. Aging* 2021, 16, 1119–1129. [CrossRef]
- Mijnarends, D.M.; Koster, A.; Schols, J.M.G.A.; Meijers, J.M.M.; Halfens, R.J.G.; Gudnason, V.; Eiriksdottir, G.; Siggeirsdottir, K.; Sigurdsson, S.; Jónsson, P.V.; et al. Physical activity and incidence of sarcopenia: The population-based AGES—Reykjavik Study. *Age Ageing* 2016, 45, 614–620. [CrossRef]
- Fukuda, Y.; Yamamoto, K.; Hirao, M.; Nishikawa, K.; Nagatsuma, Y.; Nakayama, T.; Tanikawa, S.; Maeda, S.; Uemura, M.; Miyake, M.; et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. *Gastric Cancer* 2015, *19*, 986–993. [CrossRef]
- 31. Lieffers, J.R.; Bathe, O.F.; Fassbender, K.; Winget, M.; Baracos, V.E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. *Br. J. Cancer* **2012**, *107*, 931–936. [CrossRef]
- 32. Thelwall, S.; Harrington, P.; Sheridan, E.; Lamagni, T.; Thelwall, S.; Harrington, P.; Sheridan, E.; Lamagni, T. Impact of obesity on the risk of wound infection following surgery: Results from a nationwide prospective multicentre cohort study in England. *Clin. Microbiol. Infect.* **2015**, *21*, 1008.e1–1008.e8. [CrossRef] [PubMed]
- 33. Huttunen, R.; Syrjänen, J. Obesity and the risk and outcome of infection. Int. J. Obes. 2013, 37, 333–340. [CrossRef] [PubMed]
- 34. Moisey, L.L.; Mourtzakis, M.; Cotton, A.B.; Premji, T.; Heyland, D.K.; Wade, E.C.; Bulger, E.; Kozar, A.R. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. *Crit. Care* **2013**, *17*, R206. [CrossRef] [PubMed]
- 35. Bang, J.-Y.; Jun, I.-G.; Lee, J.-B.; Ko, Y.-S.; Kim, K.-W.; Jeong, J.-H.; Kim, S.-H.; Song, J.-G. Impact of Sarcopenia on Acute Kidney Injury after Infrarenal Abdominal Aortic Aneurysm Surgery: A Propensity Matching Analysis. *Nutrients* 2021, 13, 2212. [CrossRef]
- 36. Landi, F.; Liperoti, R.; Russo, A.; Giovannini, S.; Tosato, M.; Capoluongo, E.; Bernabei, R.; Onder, G. Sarcopenia as a risk factor for falls in elderly individuals: Results from the ilSIRENTE study. *Clin. Nutr.* **2012**, *31*, 652–658. [CrossRef]
- 37. Puthucheary, Z.A.; Rawal, J.; McPhail, M.; Connolly, B.; Ratnayake, G.; Chan, P.; Hopkinson, N.S.; Padhke, R.; Dew, T.; Sidhu, P.S.; et al. Acute Skeletal Muscle Wasting in Critical Illness. *JAMA* 2013, *310*, 1591–1600. [CrossRef]
- Lanza, E.; Masetti, C.; Messana, G.; Muglia, R.; Pugliese, N.; Ceriani, R.; de Nalda, A.L.; Rimassa, L.; Torzilli, G.; Poretti, D.; et al. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. *PLoS ONE* 2020, *15*, e0232371. [CrossRef]
- Van der Werf, A.; Langius, J.A.; De Van Der Schueren, M.A.; Nurmohamed, S.A.; Van Der Pant, K.A.; Blauwhoff-Buskermolen, S.; Wierdsma, N.L. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. *Eur. J. Clin. Nutr.* 2018, 72, 288–296. [CrossRef]
- 40. Gingrich, A.; Volkert, D.; Kiesswetter, E.; Thomanek, M.; Bach, S.; Sieber, C.C.; Zopf, Y. Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients. *BMC Geriatr.* **2019**, *19*, 120. [CrossRef]
- 41. Chen, X.; Mao, G.; Leng, S.X. Frailty syndrome: An overview. Clin. Interv. Aging 2014, 9, 433–441. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.